Gene Biotherapeutics (CRXM) 10-K 15 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 30, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'CRXM	'	'
Entity Registrant Name	'Taxus Cardium Pharmaceuticals Group Inc.	'	'
Entity Central Index Key	'0000772320	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	9,652,710	'
Entity Public Float	'	'	$8.70

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$22,489	$2,328,074
Accounts receivable	0	22,320
Inventory, net	159,831	682,094
Current assets of discontinued operations	0	852,546
Prepaid expenses and other assets	309,200	403,705
Total current assets	491,520	4,288,739
Property and equipment, net	30,196	52,115
Investment	1,699,672	0
Deposit on investment option	435,000	435,000
Technology licenses, net	0	1,198,318
Other long term assets	129,989	175,808
Assets of discontinued operations	0	1,658,898
Total assets	2,786,377	7,808,878
Current liabilities:	'	'
Accounts payable	990,279	374,126
Accrued liabilities	611,007	376,512
Current liabilities of discontinued operations	0	642,080
Current liabilities	1,601,286	1,392,718
Deferred rent	0	50,370
Total liabilities	1,601,286	1,443,088
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Common stock, $0.0001 par value; 200,000,000 shares authorized; issued and outstanding 8,810,624 at December 31, 2013 and 6,460,586 at December 31, 2012	12,956	12,922
Additional paid-in capital	106,500,753	102,767,193
Deficit accumulated during development stage	-105,328,618	-96,414,325
Total stockholders' equity	1,185,091	6,365,790
Total liabilities and stockholders' equity	2,786,377	7,808,878
Convertible Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Series A Convertible Preferred stock, $0.0001 par value; 40,000,000 shares authorized; issued and outstanding 1,500 at December 31, 2013 and 0 at December 31, 2012, with liquidation preferences of $1,000	$0	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	8,810,624	6,460,586
Common stock, shares outstanding	8,810,624	6,460,586
Convertible Preferred Stock [Member]	'	'
Series A Convertible Preferred stock, par value	$0.00	$0.00
Series A Convertible Preferred stock, shares authorized	40,000,000	40,000,000
Series A Convertible Preferred stock, shares issued	1,500	0
Series A Convertible Preferred stock, shares outstanding	1,500	0
Series A Convertible Preferred stock, liquidation preference value	$1,000	$1,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		120 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenues	'	'	'
Product sales	$109,200	$59,409	$894,518
Grant revenues	0	0	1,623,160
Total revenues	109,200	59,409	2,517,678
Cost of goods sold	-69,160	-54,151	-506,225
Gross profit	40,040	5,258	2,011,453
Operating expenses	'	'	'
Research and development	-2,037,370	-2,581,094	-46,044,098
Selling, general and administrative	-4,908,919	-5,717,985	-48,462,277
Total operating expenses	-6,946,289	-8,299,079	-94,506,375
Loss from operations	-6,906,249	-8,293,821	-92,494,922
Change in fair value of derivative liabilities	0	64,157	10,395,709
Gain on warrant exchange	0	0	473,872
Interest income	217	6,592	1,583,855
Interest expense	-771	-4,042	-7,127,025
Net loss from continuing operations	-6,906,803	-8,227,114	-87,168,511
Net loss from discontinued operations	-2,007,490	-96,196	-24,568,710
Gain on sale of business unit	0	0	6,408,603
Net loss	-8,914,293	-8,323,310	-105,328,618
Deemed dividend on preferred stock	-405,872	0	'
Net loss applicable to common stockholders	($9,320,165)	($8,323,310)	'
Net loss per share-basic and diluted	'	'	'
Net loss from continued operations	($1.04)	($1.39)	'
Net Loss from discontinued operations	($0.29)	($0.02)	'
Net loss per share-basic and diluted	($1.33)	($1.41)	'
Weighted average number of common shares outstanding	6,995,676	5,922,717	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Deficit Accumulated During Development Stage [Member]
	USD ($)	USD ($)	USD ($)	Series A Preferred Stock [Member]	USD ($)	Series A Preferred Stock [Member]	USD ($)	Series A Preferred Stock [Member]	USD ($)
				USD ($)				USD ($)
Balance at Dec. 31, 2011	$6,084,930	'	$8,610	'	$0	'	$94,167,335	'	($88,091,015)
Balance, Shares at Dec. 31, 2011	'	'	4,828,963	'	0	'	'	'	'
Reclassification of derivative liabilities that no longer contain price protection provisions	21,349	'	'	'	'	'	21,349	'	'
Stock option compensation	169,746	'	'	'	'	'	169,746	'	'
Issuance of common stock for acquisition of To Go Brands	2,016,000	'	960	'	0	'	2,015,040	'	'
Issuance of common stock for acquisition of To Go Brands, Shares	'	'	480,000	'	0	'	'	'	'
Issuance of common stock for cash, net of issuance costs	6,396,311	'	3,352	'	0	'	6,392,959	'	'
Issuance of common stock for cash, net of issuance costs, Shares	'	'	1,151,487	'	0	'	'	'	'
Exercise of warrants	764	'	'	'	'	'	764	'	'
Exercise of warrants, Shares	'	'	136	'	0	'	'	'	'
Net loss	-8,323,310	'	'	'	'	'	'	'	-8,323,310
Balance at Dec. 31, 2012	6,365,790	'	12,922	'	0	'	102,767,193	'	-96,414,325
Balance, Shares at Dec. 31, 2012	'	'	6,460,586	'	0	'	'	'	'
Stock option compensation	40,750	'	'	'	'	'	40,750	'	'
Issuance of common stock for cash, net of issuance costs	65,743	3,627,101	34	0	'	'	65,709	3,627,101	'
Issuance of common stock for cash, net of issuance costs, Shares	'	'	17,187	0	'	4,012	'	'	'
Issuance of common stock on conversion of preferred stock	0	'	0	'	0	'	0	'	'
Issuance of common stock on conversion of preferred stock, Shares	'	'	2,332,851	'	-2,512	'	'	'	'
Net loss	-8,914,293	'	'	'	'	'	'	'	-8,914,293
Balance at Dec. 31, 2013	$1,185,091	'	$12,956	'	$0	'	$106,500,753	'	($105,328,618)
Balance, Shares at Dec. 31, 2013	'	'	8,810,624	'	1,500	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		120 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash Flows From Operating Activities	'	'	'
Net loss	($8,914,293)	($8,323,310)	($105,328,618)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Gain on sale of discontinued operation	0	0	-6,408,603
Gain on sale of warrants	0	0	-518,622
Loss on abandonment of leaseholds	0	0	135,344
Depreciation	72,357	107,823	2,183,485
Amortization-intangibles	123,280	38,308	2,857,781
Amortization-debt discount	0	0	5,291,019
Amortization-deferred financing costs	0	0	925,859
Amortization and write-off-technology and licenses	100,807	134,409	337,489
Write-off of technology licenses	1,097,511	0	1,097,511
Provision for obsolete inventory	-62,482	-40,852	96,666
Reserve for product returns	-76,000	76,000	0
Change in fair value of warrants	0	-64,157	-10,395,709
Common stock and warrants issued for services and reimbursement of expenses	0	0	203,882
Stock based compensation expense	40,750	169,746	7,638,571
In-process purchased technology	0	0	2,027,529
Deferred rent	-50,370	-67,943	0
Changes in operating assets and liabilities	'	'	'
Accounts receivable	222,110	-182,675	118,423
Inventories	620,698	-305,603	-1,925,194
Prepaid expenses and other assets	90,130	-332,465	-423,129
Deposits	54,847	4,770	-130,133
Accounts payable	517,490	-181,812	2,221,986
Accrued liabilities	137,789	-244,804	-325,239
Net cash used in operating activities	-6,025,376	-9,212,565	-100,319,702
Cash Flows From Investing Activities	'	'	'
In-process technology purchased from Tissue Repair Company	0	0	-1,500,000
Fee paid to list shares issued for technology and product license	0	0	-65,000
Purchases of property and equipment	-23,053	-15,866	-2,855,470
Cash acquired in acquisitions	0	288,151	1,839,951
Net cash provided by (used in) investing activities	-23,053	272,285	-2,580,519
Cash Flows From Financing Activities	'	'	'
Proceeds from officer loan	0	0	62,882
Restricted cash-collateral for letter of credit	50,000	150,000	0
Proceeds from the exercise of warrants, net	0	764	1,259,212
Proceeds from debt financing agreement, net of debt issuance costs of $871,833	0	0	14,378,167
Proceeds from the sale of business unit	0	0	11,250,000
Repayment of debt	0	0	-15,750,000
Proceeds from sales of preferred and common stock, net of issuance costs of $67,386	3,692,844	6,396,311	91,722,449
Net cash provided by financing activities	3,742,844	6,547,075	102,922,710
Net increase (decrease) in cash	-2,305,585	-2,393,205	22,489
Cash and cash equivalents at beginning of period	2,328,074	4,721,279	0
Cash and cash equivalents at end of period	22,489	2,328,074	22,489
Supplemental Disclosures of Cash Flow Information:	'	'	'
Cash paid for interest	1,438	4,248	1,394,487
Cash paid for income taxes	3,200	2,400	31,762
Non-Cash Activity:	'	'	'
Subscription receivable for common shares	0	0	17,000
Common stock issued for repayment of loans	0	0	62,882
Stock issued for technology license fee	0	0	1,870,000
Net assets acquired for the issuance of common stock (exclusive of cash acquired)	0	1,727,849	7,551,849
Warrants exchanged for stock	0	0	-901,139
Reclassification of derivative liabilities with expired price protection provisions	0	-21,349	-4,045,702
Issuance of note for accrued milestone payment	0	0	500,000
Sale of To Go Brands for preferred stock	$1,699,672	$0	$1,699,672

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	0 Months Ended	12 Months Ended		120 Months Ended
	Mar. 12, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Statement Of Cash Flows [Abstract]	'	'	'	'
Debt issuance cost, from debt financing agreement	$793,449	$871,833	$871,833	$871,833
Common and preferred stock issuance costs	'	$67,386	$67,386	$67,386

Organization_and_Liquidity

Organization and Liquidity	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization and Liquidity	'
	Note 1. Organization and Liquidity
	Organization
	Taxus Cardium Pharmaceuticals Group, Inc. (the “Company,” “Cardium,” “we,” “our” and “us”) was incorporated in Delaware in December 2003. We are a development-stage regenerative medicine biotechnology company. We are focused on the development of advanced regenerative therapeutics designed to promote the activation and growth of (1) microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and (2) granulation tissue as a treatment for chronic non-healing wounds. We have a commercial FDA-cleared wound care product, a late clinical stage cardiovascular gene therapy product candidate and corresponding technology platforms as outlined below. We also own non-core interests in the Healthy Brands Collective, a health products company, and LifeAgain Insurance Solutions, Inc., a medical analytics business.
	In October 2005, we acquired a portfolio of biologic growth factors and related delivery techniques from the Schering AG Group (now part of Bayer AG) for potential use in treating ischemic and other cardiovascular conditions.
	In March 2006, we acquired the technologies and products of InnerCool Therapies, Inc., a medical technology company in the emerging field of therapeutic hypothermia, or patient temperature modulation, whose systems and products are designed to rapidly and controllably cool the body to reduce cell death and damage following acute ischemic events such as cardiac arrest and stroke, and to potentially lessen or prevent associated injuries such as adverse neurologic outcomes.
	In August 2006, we acquired rights to assets and technologies of Tissue Repair Company, a company focused on the development of growth factor therapeutics for the potential treatment of tissue wounds such as chronic diabetic wounds, and whose product candidate, Excellagen is initially being developed as a single administration therapeutic for the treatment of non-healing, neuropathic diabetic foot ulcers. Tissue Repair Company is operated as a wholly-owned subsidiary of Cardium.
	On July 24, 2009, we sold all of the assets and liabilities of our InnerCool Therapies business to Philips Electronics North America Corporation for $11.25 million, as well as the transfer of approximately $1.5 million in trade payables.
	On September 28, 2012 we acquired substantially all of the business assets and product portfolio of privately-held To Go Brands, Inc. To Go Brands develops, markets and sells a portfolio of products, including nutraceutical powder mixes, supplements and chews intended to support healthy lifestyles. These products are sold through food, drug and mass channels at retailers including Whole Foods®, CVS®, Kroger®, GNC®, Jewel-Osco®, Ralph’s Supermarkets®, Meijer®, and the Vitamin Shoppe® and from the Company’s web-based store.
	On November 15, 2013, the Company sold its To Go Brands® business to Healthy Brands Collective® in exchange for an equity stake in Healthy Brands preferred stock which, at the time of the transaction, was convertible into approximately 4% of their fully-diluted common stock, and the assumption of approximately $370,000 of liabilities. Healthy Brands Collective® is a fast growing private company that has acquired a portfolio of eight independent brand product platforms (prior to To Go Brands).
	Our business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address significant unmet medical needs, and having definable pathways to commercialization. We intend to consider various corporate development transactions designed to place our product candidates into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products. Such transactions could involve the sale, partnering or other monetization of particular product opportunities or businesses.
	We are a development stage company. We have yet to generate positive cash flows from operations, and are essentially dependent on debt and equity funding to finance our operations.
	Reverse Stock Split
	On July 17, 2013, pursuant to board and stockholder approval, we filed a Certificate of Amendment to our Restated Certificate of Incorporation with the State of Delaware to affect a reverse split of our outstanding common stock, par value $0.0001 per share, in a ratio of 1:20. The effective date of the reverse stock split was July 18, 2013.
	On that date, every 20 shares of outstanding common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each resulting fractional share of common stock was rounded down to one whole share. The reverse stock split reduced the number of shares of common stock outstanding from 134,366,340 to 6,718,317.
	All common stock and per share amounts contained in the consolidated financial statements included in this report have been retroactively adjusted to reflect the 1 for 20 reverse stock split, as if such split had been effective at the beginning of the earliest period reported.
	Liquidity and Capital Resources
	As of December 31, 2013, we had $22,000 in cash and cash equivalents. Our working capital deficit at December 31, 2013 was approximately $1,110,000.
	During the period subsequent to December 31, 2013, cash flows from financing activities include the sale of 714,286 shares of common stock in transactions for net proceeds of $492,500.
	Net cash used in operating activities was $6.0 million for the year ended December 31, 2013 compared to $9.2 million for the year ended December 31, 2012. The increase in net cash used in operating activities was due primarily to testing and process validation costs for the initial inventory of our Excellagen topical treatment gel. Since inception, our operations have consumed substantial amounts of cash and we have had only limited revenues. From inception (December 22, 2003) to December 31, 2013, net cash used in operating activities has been $100.3 million.
	Our primary source of liquidity has been cash from financing activities and in particular proceeds from sales of our debt and equity securities. Net cash provided by financing activities was $3.7 million for the year ended December 31, 2013. This included a preferred stock equity financing with one institutional investor of 4,012 shares of Cardium Series A Convertible Preferred Stock priced at $1,000 per share with no warrant coverage for net proceeds of $3.7 million. From inception (December 22, 2003) to December 31, 2013 net cash provided by financing activities has been $102.9 million.
	Net cash used in investing activities for the year ended December 31, 2013 was $23,000. Net cash used in investing activities since inception has been approximately $2.6 million. At December 31, 2013 we did not have any significant capital expenditure requirements.
	We anticipate that negative cash flow from operations will continue for the foreseeable future. We do not have any unused credit facilities. As long as any shares of our Series A Convertible Preferred Stock are outstanding, we have agreed that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, incur any liens other than specified “Permitted Liens”. We intend to secure additional working capital through sales of additional debt or equity securities to finance our operations. Our principal business objective is to complete an additional strategic licensing agreement to advance sales of the Excellagen product family and/or another corporate transaction. If we fail to enter into an additional strategic licensing arrangement or generate sufficient product sales, we will not generate sufficient cash flows to cover our operating expenses.
	On September 28, 2010, we entered into a Sale Agreement with Brinson Patrick Securities Corporation which enables us to use Brinson Patrick as a sales manager to sell shares of our common stock on a best efforts basis from time to time in “at-the-market” transactions pursuant to our shelf registration statement. During the year ended December 31, 2013 we raised $65,743 under this agreement, the majority of which was raised during the first quarter of 2013. The Sale Agreement required that we register the sale of our shares to Brinson Patrick Securities Corporation on a shelf registration statement on Form S-3. Because our common stock is no longer listed on a national exchange, we are not eligible to use a Form S-3 registration statement. Accordingly we do not anticipate additional sales under the Sales Agreement unless and until we regain listing on a national exchange.
	Our history of recurring losses and uncertainties as to whether our operations will become profitable raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should we be unable to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2—Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying financial statements have been prepared in accordance with authoritative guidance for development stage enterprises.
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short term maturities of these instruments.
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include reserve for product returns, reserve for inventory, and valuing options and warrants using Option Pricing Models.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Taxus Cardium Pharmaceuticals Group, Inc. and its wholly-owned subsidiaries, Tissue Repair Company, To Go Brands, Inc. (a business that is presented as a discontinued operation as described in Note 3) and LifeAgain Insurance Solutions, Inc. (collectively, the “Company”). All significant inter-company transactions and balances have been eliminated in consolidation.
	Business Acquisitions.
	Business combinations are accounted for using the acquisition method of accounting in accordance with ASC 850 “Business Combinations.” The cost of an acquisition is measured as the fair value of the consideration transferred on the acquisition date. When the Company acquires a business, it assesses the acquired assets and liabilities assumed for the appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions at the acquisition date. The excess of the total consideration transferred over the net identifiable assets acquired and liabilities assumed is recognized as goodwill. If this consideration is lower than the fair value of the identifiable net assets acquired, the difference is recognized as a gain on business acquisition. Acquisition costs are expensed as incurred and included in general and administrative expenses in our consolidated statements of operations.
	Cash and Cash Equivalents
	We consider all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
	Concentration of Credit Risk
	Financial instruments that potentially subject us to significant concentrations of credit risk consist of cash and cash equivalents. At times, our cash and cash equivalents may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. As of December 31, 2013, we had no cash and cash equivalent balances in excess of the federally insured limit of $250,000.
	Accounts Receivable
	Accounts receivable are stated at cost less an allowance for doubtful accounts, which reflects our estimate of balances that will be not collected. The allowance is based on the history of past write-offs, the aging of balances, collections experience and current credit conditions. Additions to the allowance for doubtful accounts include provisions for bad debt and deductions to the allowance for doubtful accounts including customer write-offs. The Company has a low occurrence of credit losses and therefore does not believe an allowance for doubtful accounts in necessary.
	Inventory
	Inventories are stated at lower of cost or market and consist of raw materials associated with the Excellagen product. Inventories are valued on a first-in, first-out (FIFO) basis. The Company records reserves for inventories that are obsolete or exceed anticipated demand or carried at an amount that exceeds management’s estimate of net realizable. In establishing such reserves, management considers historical sales of identical and/or similar goods, product development plans and expected market demand.
	Property and Equipment
	Property and equipment are stated at cost and include equipment, installation costs and materials. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the useful lives or the term of the respective lease.
	Expenditures for maintenance and repairs, which do not extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in general and administrative expenses in the statement of operations.
	Technology Licenses
	Technology licenses represent two distinct licenses that we acquired for the use of fully developed product formulas that we planned to use as part of our initiative to create a portfolio of nutraceutical products. We planned to market these products to consumers principally through convenience stores, pharmacy chains, and wholesale clubs that we gained access to as a result of our acquisition of To Go Brands (Note 3). These licenses were initially recorded at cost and were being amortized over the fixed term of the underlying agreements, which we believed was approximately equal to the useful lives of the underlying product formulas. We periodically tested the carrying amounts of these licenses for possible impairment in accordance with the guidelines enumerated under Accounting Standards Codification (“ASC”) 350 “Intangibles-Goodwill and Other.” Under ASC 350, intangible assets with definite lives are periodically tested for impairment based on an analysis of undiscounted cash flows (as described below). Management has determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and the write-off of the unamortized balance of $1.1 million of our technology licenses associated with that product line.
	Long-Lived Assets
	Long-lived assets to be held and used, including property, plant and equipment as well as intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable such as:
		•		a significant decline in the observable market value of an asset;
		•		a significant change in the extent or manner in which an asset is used; or
		•		a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
	Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell. We do not believe there was any impairment of long-lived assets at December 31, 2013 but determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and to fully reserve the unamortized balance of $1.1 million of our technology licenses which was focused on that product line.
	Preferred Stock
	We apply the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of our preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
	Revenue Recognition
	The Company’s revenues principally consist of sales of Excellagen product. The Company applies the revenue recognition principles set forth under the Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 104. Accordingly, revenue from product sales is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. These criteria are met when the risk of ownership and title passes to the Company’s customers.
	Research and Development
	In accordance with ASC Topic 730 research and development costs are expensed as incurred. Research and development expenses consist of purchased technology, purchased research and development rights and outside services for research and development activities associated with product development. In accordance with ASC Topic 730, the cost to purchase such technology and research and development rights are required to be charged to expense if there is currently no alternative future use for this technology and, therefore, no separate economic value.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not to be sustained upon examination.
	Common Stock Purchase Warrants
	We account for the issuance of common stock purchase warrants issued in connection with capital financing transactions in accordance with the provisions of ASC Topic 815. Based upon the provisions of ASC Topic 815, we classify as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). We classify as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
	Loss Per Common Share
	We compute loss per share, in accordance with ASC Topic 260 which requires dual presentation of basic and diluted earnings per share.
	Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss per common share for the years ended December 31, 2013 or 2012 because their effect would be anti-dilutive.
	As of December 31, 2013 potentially dilutive securities consist of outstanding stock options and warrants to acquire 1,122,830 shares of our common stock. As of December 31, 2012, potentially dilutive securities consisted of outstanding stock options and warrants to acquire 1,547,071 shares of our common stock.
	Stock-Based Compensation
	Stock-based compensation costs are recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.
	Total stock-based compensation expense included in the consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
			December 31,
			2013		2012
	Research and development		$	5,997	$	23,883
	General and administrative			34,753		145,863
	Total stock-based compensation		$	40,750	$	169,746
	Deferred Rent
	Rent expense is recorded on the straight-line method based on the total minimum rent payments required over the term of the lease. The cumulative difference between the lease expense recorded under this method and the contractual lease payment terms is recorded as deferred rent.
	Recent Accounting Pronouncements
	We do not believe that any recently issued accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Disposal_of_LongLived_Assets

Disposal of Long-Lived Assets	12 Months Ended
	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Disposal of Long-Lived Assets	'
	NOTE 3—Disposal of Long-Lived Assets
	In accordance with the provisions of ASC topic 360 (formerly SFAS No. 144), “Accounting for the Impairment or Disposal of Long-Lived Assets,” the disposal of our To Go Brands Inc. business segment is presented as assets and liabilities held for sale and as a discontinued operation in the accompanying consolidated financial statements.
	Assets and liabilities of discontinued operations
	The major categories of assets and liabilities of discontinued operations included in the consolidated balance sheet at December 31, 2012 were as follows:
	Assets of discontinued operations:
	Accounts receivable		306,633
	Inventories, net		492,229
	Prepaid expenses and other current assets		53,684
	Property, plant and equipment, net		45,467
	Goodwill		584,711
	Intangibles, net		1,019,692
	Long term assets		9,028
	Total assets of discontinued operations	$	2,511,444
	Liabilities of discontinued operations:
	Accounts payable	$	403,735
	Accrued liabilities		238,345
	Total liabilities of discontinued operations	$	642,080
	The following results of operations of To Go Brands, Inc. and the expense associated with the write-off of the remaining recorded value of the technology licenses associated with the nutraceutical business are presented as a loss from a discontinued operation in the consolidated statements of operations:
		For the years  ended						Period from
		December 31,						December 22,
								2003
								(Inception) to
								December 31,
		2013			2012			2009
	Revenues
	Product sales	$	1,728,177		$	725,909		$	2,454,086
	Cost of goods sold		1,002,064			382,914			1,384,978
	Gross profit		726,113			342,995			1,069,108
	Operating expenses
	Research and development		128,215			40,227			168,442
	Selling, general and administrative		1,507,210			398,761			1,905,971
	Total operating expenses		1,635,425			438,988			2,074,413
	Loss from operation		(909,312	)		(95,993	)		(1,005,305	)
	Interest, net		(667	)		(203	)		(870	)
	Net loss from discontinued operations of To Go Brands, Inc.	$	(909,979	)	$	(96,196	)	$	(1,006,175	)
	Write-off of technology licenses associated with the nutraceutical product lines		(1,097,511	)		0			(1,097,511	)
	Net loss from discontinued operations	$	(2,007,490	)	$	(96,196	)	$	(2,103,686	)
	On November 15, 2013, we closed the sale of our To Go Brands, Inc. business unit to Healthy Brands Collective. The purchase price was 33,441 shares of preferred stock of Cell-nique(parent company of Healthy Brands). Since Cell-nique Corporation is a private company we have recorded the value of those shares of preferred stock on our balance sheet as an investment in Cell-nique Corporation., at the net asset value of the assets transferred and liabilities assumed by Cell-nique Corporation. The Company has elected to defer recognition of any gain on the sale of the To Go Brands business until such time that the realization of the gain is reasonably assured. Accordingly, the Company is accounting for its investment in Cell-nique using the cost method of accounting, in which the cost is equal to the carrying amount of the net assets sold to Cell-nique as of the date that the transaction closed. The Company will periodically review the carrying amount of its investment in Cell-nique to determine whether the value is impaired or a write down may be necessary for an other than temporary decline in value.
	The Cell-nique preferred shares are convertible into Cell-nique common stock at the option of the Company which would currently represent approximately 4% of the fully-diluted voting interests of Cell-nique. These shares also accrue dividends at the rate of 8% per annum, are mandatorily convertible into common shares under certain circumstances, and feature customary rights of priority and a liquidation preference in the event of a dissolution or winding up Cell-nique’s affairs or upon the occurrence of other deemed liquidation events described in Cell-nique’s articles of incorporation.
	The following is the calculation of the net assets on the sale of To Go Brands, Inc.
	Net assets sold:
	Accounts receivable		106,843
	Prepaid expenses and other current assets		8,059
	Inventory, net		456,276
	Property and equipment, net		18,082
	Intangible assets, net		1,481,123
	Other long term assets		0
	Accounts payable		(305,072	)
	Other liabilities		(65,639	)
	Net Assets of To Go Brands, Inc. sold		1,699,672

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Note 4—Inventories
	Inventories consisted of the following:
		December 31,			December 31,
		2013			2012
	Raw materials	$	183,398		$	430,825
	Finished goods		0			313,700
			183,398			744,525
	Less provision for obsolete inventory		(23,567	)		(62,431	)
	Inventories, net	$	159,831		$	682,094

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	Note 5—Property and Equipment
	Property and equipment consisted of the following:
		December 31,
		2013			2012
	Computer and telecommunication equipment	$	425,331		$	532,069
	Machinery and equipment		31,779			31,779
	Office equipment		11,490			53,050
	Instrumentation		0			115,421
	Office furniture and equipment		223,206			480,594
	Leasehold improvements		23,053			152,774
			714,859			1,365,687
	Accumulated depreciation and amortization		(684,663	)		(1,313,572	)
	Property and equipment, net	$	30,196		$	52,115
	Depreciation and amortization of property and equipment from continuing operations totaled $44,973 and $99,332 for the years ended December 31, 2013 and 2012, respectively. For the period from December 22, 2003 (inception) through December 31, 2013 depreciation and amortization of property and equipment from continuing operations totaled $1,414,271.

Intangible_assets_and_strategi

Intangible assets and strategic investment	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Intangible assets and strategic investment	'
	Note 6—Intangible assets and strategic investment
	On November 17, 2010 we entered into a custom technology access and product license agreement with BioZone Laboratories, Inc. (“BioZone”) for the co-development and strategic licensing of a portfolio of up to 20 aesthetics, advanced skin care formulations and other products for our MedPodium product line. The agreement grants us a royalty-free license of BioZone’s technology to develop a portfolio of 20 products, customized to our product specifications. We have exclusive rights to the products developed to our specifications. The license is for a term of 10 years with an automatic 1 year renewal at our option, without any material restrictions or additional consideration. In exchange for the technology access license we paid BioZone a fee of $1.0 million. The license fee was paid through the issuance of 100,000 shares of our unregistered common stock. The license fee was being amortized over 11 years on a straight line basis; however, the Company is now primarily focused on the development of advanced regenerative medicine therapeutics and determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and to the write-off of the unamortized balance of $738,636 of this technology license which was focused on that product line.
	On December 20, 2011 we received a license for a portfolio of nutraceutical, pharmaceutical and medical food product opportunities with SourceOne Global Partners, LLC (“SourceOne”). In exchange for the license we issued 75,000 restricted shares of our common stock valued at $5.80 per share. The shares were deposited in escrow for nine months and subject to release at future dates thereafter based on our advancement of certain jointly-developed products. Under terms of the licensing arrangement, we received a fully-paid-up license to commercialize formulations of various SourceOne ingredients to be marketed as nutraceuticals, pharmaceuticals and/or medical foods. In addition, we obtained the right to designate up to ten products to be jointly developed by the parties, with cash and other resources to be contributed jointly under a profit-share arrangement. The license fee was being amortized over 10 years on a straight line basis; however, the Company is now primarily focused on the development of advanced regenerative medicine therapeutics and determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and to the write-off of the unamortized balance of $358,875 of this technology license which was focused on that product line.
	Under the SourceOne agreement, we also made a deposit on a potential equity investment in the form of unregistered, restricted shares of our common stock to acquire an option to purchase up to a 15% ownership interest in SourceOne Global Partners. The seven year option was acquired through the issuance into escrow of 75,000 shares of our common stock which were recorded at a value of $5.80 per share based on the closing price of our stock on December 19, 2011, and is exercisable for an exercise fee of $10,000. The shares of our common stock issued for the option are being held in escrow and are subject to release in four allotments at 6, 9, 12 and 18 months following the closing date. During the year ended December 31, 2012, 50,000 shares were released from the escrow account and the balance of 25,000 was released in 2013. We also have certain rights to maintain our proportionate ownership interest in SourceOne, and a right of first refusal to acquire SourceOne on the terms that SourceOne were to offer a third-party acquirer. The company has over five years remaining to determine if it will exercise this option. In the event the Company chooses not to proceed with making the investment in Source One, the non-refundable deposit would be recorded as a charge to operations.

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	Note 7—Accrued Liabilities
	Accrued Liabilities consisted of the following:
		December 31,
		2013		2012
	Payroll and benefits	$	511,098	$	376,512
	Other		99,909		0
	Total	$	611,007	$	376,512

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 8—Commitments and Contingencies
	Lease Commitments
	On September 28, 2012 with the acquisition of To Go Brands, we assumed the office for approximately 4,745 square feet of office and warehouse space in San Diego, California to be used as To Go Brands operating headquarters. The lease originally commenced in June 2012 and has a two year term. Monthly base rent is $4,270 during the first year of the lease and increases to $4,441 for the second year of the lease. In addition to monthly base rent, we are also required to pay $300 to cover the Association monthly fees. In connection with entering into this lease, the landlord holds a security deposit of $4,441 on this lease.
	On January 30, 2013 we entered into a lease for approximately 2,471 square feet of additional warehouse space in San Diego, California to be used for To Go Brands. Monthly base rent is $1,853. In connection with entering into the lease, we paid a security deposit of $1,853.
	On August 15, 2013 we entered into a lease for approximately 4,419 square feet of office space in San Diego, California to be used as our corporate headquarters. The lease commenced on September 1, 2013 once improvements were completed and has a term of 36 months from the commencement date. In addition to monthly base rent, we are also required to pay our proportionate share of any building operating expenses in excess of 2014 levels. In connection with entering into the lease, we paid a security deposit of $9,231. Monthly base rent is $9,678 during the first year of the lease and increases to $10,016 in year two and $10,367 in year three.
	Future annual minimum rental payments under the leases are as follows:
	Year Ending December 31,	Facilities
		(Operating Lease)
	2014		150,458
	2015		121,596
	2016		82,936
	Total	$	354,990
	Rent expense included in continuing operations was $435,573, and $582,146 for the years ended December 31, 2013 and 2012 respectively.
	License Fees
	In October 2005, we completed a transaction with Schering AG Group, Germany (now part of Bayer AG) and related licensors, including the University of California and New York University, for the transfer or license of certain assets and technology for potential use in treating ischemic and other cardiovascular conditions. Under the terms of the transaction, we paid Schering a $4 million fee, and would be required to pay a $10 million milestone payment upon the first commercial sale of each resulting product. We also may be obligated to pay the following future royalties to Schering: (i) 5% on net sales of an FGF-4 based product such as Generx, or (ii) 4% on net sales of other products developed based on technology transferred to Cardium by Schering. As part of the Schering transaction, we acquired rights and corresponding obligations under the Regents of the University of California (Regents) September 1995 agreement, as amended. The agreement as amended may be canceled by us at any time on 60 days’ notice, following which we would continue to be responsible only for obligations and liabilities accrued before termination. Under the agreement, we are obligated to pay (1) an annual royalty fee of 2% based on net sales of products incorporating the technology licensed under the agreement, and (2) a minimum annual royalty fee (which may be offset against the net sales-based royalty fee) $100,000 for 2010, $100,000 for 2011, $150,000 for 2012, $150,000 for 2013 and $200,000 for 2014 and thereafter, payable on February 28 of the following year. We incurred the minimum license fee in 2013 and 2012.
	Legal Proceedings
	From time to time, we may become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to intellectual property, employment, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 9—Income Taxes
	We file income tax returns in the United States (federal) and California. In most instances, we are no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2010.
	ASC 740 clarifies the accounting and reporting for uncertainties in income tax law. It prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions. Differences between a tax position taken or expected to be taken in the Company’s tax returns and the amount of benefit recognized and measured in the financial statements result in unrecognized tax benefits, which are recorded in the balance sheet as either a liability for unrecognized tax benefits or reductions to recorded tax assets, as applicable. As of December 31, 2013 and 2012, no liability for unrecognized tax benefits was required to be recorded.
	Interest costs related to unrecognized tax benefits are required to be calculated and would be classified as interest expense in the consolidated statement of operations. Penalties would be recognized as a component of general and administrative expenses. No interest and penalties were recorded during the years ended December 31, 2013 and December 31, 2012.
	We had U.S. federal and state net operating loss carryovers of $92.5 million and $88.2 million as of December 31, 2013 and 2012, respectively. These net operating losses are subject to Internal Revenue Code Section 382, which could result in limitations on the amount of such losses that could be utilized during any taxable year. The net operating losses begin to expire in 2023 for federal income purposes and in 2013 for state income tax purposes.
	The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those net operating losses are available. We consider projected future taxable income and tax planning strategies in making its assessment. At present, we do not have a sufficient history of income to conclude that it is more-likely-than-not that we will be able to realize all of our tax benefits in the near future and therefore we have established a valuation allowance for the full value of the deferred tax asset.
	A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of any portion or all of the valuation. For the years ended December 31, 2013 and 2012 the change in the valuation allowance was $1,530,946 and $4,417,362, respectively.
	Our net deferred tax asset consisted of the following at December 31, 2013 and 2012:
		December 31,
		2013			2012
	Deferred tax asset:
	Net operating loss carryforwards	$	36,837,171		$	35,135,946
	Deferred compensation		881,025			881,025
	Depreciation and amortization		886,149			944,369
	License impairment		437,187			0
	Deferred rent		0			20,065
	Research and development credit		194,132			0
	Accrued expenses		97,326			100,936
	Other		137,611			57,643
	Total deferred tax assets		39,470,601			37,139,984
	Less: Valuation allowance		(39,470,601	)		(37,139,984	)
	Net deferred tax asset		—			—
	The income tax provision (benefit) from income taxes consists of the following at December 31, 2013 and 2012:
		Years Ended December 31,
		2013			2012
	Federal
	Current	$			$
	Deferred		(1,306,714	)		(3,770,936	)
	State
	Current
	Deferred		(224,232	)		(646,426	)
	Total	$	(1,530,946	)	$	(4,417,362	)
	Change in valuation allowance		1,530,946			4,417,362
	Income tax provision (benefit)	$	—		$	—
	As a result of our significant operating loss carryforwards and the corresponding valuation allowance, no income tax benefit was recorded at December 31, 2013 or 2012. The provision for income taxes using the statutory federal tax rate as compared to our effective tax rate is summarized as follows:
		December 31,
		2013			2012
	Expected U.S. federal statutory rate		(34.0	)%		(34.0	)%
	State income taxes, net of federal benefit		(5.8	)%		(5.8	)%
	Deferred tax true-up		18.7	%		(13.5	)%
	R&D credit		(1.4	)%		0	%
	Other permanent differences		0.3	%		0.3	%
			(22.2	)%		(53.0	)%
	Change in valuation allowance		22.2	%		53	%
	Totals		0	%		0	%

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	Note 10—Stockholders’ Equity
	Common Stock
	Cardium was incorporated in Delaware on December 22, 2003. On December 31, 2003, we sold 85,000 shares of our common stock to our founders and executives for $17,000. On April 1, 2005, we issued an additional 190,000 shares of our common stock (of which 182,500 shares were issued to our co-founders and the remainder was issued to another employee of Cardium), in exchange for services and reimbursement of expenses valued at $38,000.
	On May 19, 2005, our Board of Directors and stockholders approved an increase in our authorized shares of common stock from 5,500,000 shares to 100,000,000 shares and a change in the par value of our shares of common stock from $0.001 to $0.0001.
	On May 20, 2005, we issued 17,500 shares of our common stock to our co-founders in exchange for services and reimbursement of expenses valued at $3,500. On July 1, 2005, we sold 100,000 shares of our common stock for $20,000 to one of our founders.
	On October 20, 2005, we completed a reverse merger with Aries Ventures Inc., a publicly-traded “shell” company, whereby a newly formed and wholly-owned subsidiary of Aries was merged with and into Cardium. At the time of the reverse merger, Cardium had 392,500 shares of its common stock outstanding and Aries had 101,611 shares of its common stock outstanding.
	In connection with the reverse merger, a three year warrant to purchase 20,000 shares of our common stock at an exercise price of $35.00 per share was issued to an Aries stockholder who held of record or beneficially more than 45% of the outstanding common stock of Aries before the reverse merger, as consideration for such stockholder’s agreement not to sell any of such stockholder’s shares for a specified period of time. These warrants expired in October 2008.
	Concurrently with the reverse merger, we closed a private placement of 966,282 shares of common stock at a purchase price of $30.00 per share and received net proceeds of $25,542,389. Investors who invested at least $1,000,000 in shares of common stock received a three-year warrant to buy 10% of the number of shares of common stock purchased in the private placement, at an exercise price of $35.00 per share. Warrants to purchase 21,213 shares of common stock, in the aggregate, were issued to such investors. These warrants expired in October 2008.
	On March 8, 2006, as described in Note 3 above, we acquired substantially all of the assets of Innercool Therapies, Inc. As partial consideration, we issued to the seller 125,000 shares of our common stock.
	On March 9, 2007, we closed a private placement of 431,800 shares of common stock at a purchase price of $50.00 per share and received net proceeds of approximately $20 million. Investors received five-year warrants to buy up to 35% of the number of shares of common stock purchased in the private placement, at an exercise price of $75.00 per share. Warrants to purchase approximately 151,130 shares of common stock, in the aggregate, were issued to such investors. These warrants had a price protection provision which was triggered on January 31, 2008 and therefore were reduced to an exercise price of $40.00.
	In connection with the private placement, we incurred selling commissions, and expenses payable to the placement agent, totaling approximately $1,480,300, and legal, accounting and other fees and expenses totaling approximately $100,000 In addition, a five-year warrant to purchase 25,908 shares of our common stock was issued to the placement agent at an exercise price of $75.60 per share.
	In November 2007, we entered into a Loan and Security Agreement with Life Sciences Capital, LLC whereby we obtained debt financing in the principal amount of $5 million to be used for general working capital purposes. The proceeds were immediately made available to us under this credit agreement. In connection with this financing, we issued a warrant to Life Sciences Capital, LLC to purchase 4,666 shares of our common stock at an exercise price of $75.00. We also recorded deferred financing costs in the amount of $108,500 in connection with this debt financing.
	On January 31, 2008, we completed a registered direct offering of our common stock that resulted in the sale of 132,750 shares, in the aggregate, of our common stock at a purchase price of $40.00 per share. We received gross proceeds of approximately $5,300,000, before placement agent fees and offering expenses of approximately $400,000. At December 31, 2012 warrants to purchase 51,428 shares of our common stock remain outstanding. The warrants had an exercise price of $40.00 and expired in January of 2013.
	On June 27, 2008, we completed a follow-on registered direct offering of our common stock that resulted in the sale of 81,250 shares, in the aggregate, of our common stock at a purchase price of $40.00 per share. We received gross proceeds of approximately $3,250,000, before placement agent fees and offering expenses of approximately $224,000. Warrants to purchase 118,575 shares of our common stock were issued with this transaction. 113,750 of these warrants had an exercise price of $10.00 and 4,825 had an exercise price of $45.80. The warrants expired in June of 2013.
	On July 18, 2008, we completed a second follow-on registered direct offering of our common stock that resulted in the sale of 83,500 shares, in the aggregate, of our common stock at a purchase price of $40.00 per share. We received gross proceeds of approximately $3,340,000, before placement agent fees, offering expenses and expense reimbursements of approximately $330,000. Warrants to purchase 121,450 shares of our common stock were issued with this transaction. 116,900 had an exercise price of $10.00 and 4,550 had an exercise price of $44.00. The warrants expired in June of 2013.
	On November 5, 2008, we completed a secured debt financing pursuant to the terms of a Note and Warrant Purchase Agreement entered into with certain accredited investors. Under the terms of the purchase agreement we issued notes in the aggregate principal amount of $6 million to the investors, and five year warrants to purchase an additional 469,331 shares of our common stock, in the aggregate, at an exercise price of $40.00 per share. These warrants expired in November of 2013.
	On March 5, 2009 we completed a $3.5 million financing in the form of senior subordinated secured debt with accompanying warrants to purchase 75,250 shares of our common stock. The warrants were fully exercisable when issued, have a five year term and an exercise price of $40.00. We received gross proceeds of approximately $3.5 million, less placement agent fees and offering expenses of approximately $252,000. In addition, we issued warrants to purchase 4,515 shares of common stock to the placement agent on the same terms as the warrants issued to the lenders. At December 31, 2013 all warrants issued in this transaction remain outstanding.
	On June 23, 2009 we completed a $750,000 unsecured debt financing with accompanying warrants to purchase 25,125 shares of our common stock. The warrants were fully exercisable when issued, have a five year term and an exercise price of $40.00. These warrants have subsequently been repriced to $10.00. We received aggregate gross proceeds of approximately $750,000 before placement agent fees and offering expenses of approximately $50,000. In addition, we issued warrants to purchase 603 shares of common stock to the placement agent on the same terms as the warrants issued to the lenders. At December 31, 2013 all warrants issued in this transaction remain outstanding.
	In September 16, 2009, we sold an aggregate of 150,000 at a price of $30.00 per share of our common stock and 112,500 warrants to common stock to certain institutional investors in exchange for gross proceeds of $4.2 million, net of issuance costs. Each investor received warrants to purchase a number of shares equal to 75% of the number of shares of common stock purchased by the investor in the offering. The exercise price of the warrants is $35.40. In addition, the placement agent for the September financing received 7,500 warrants to purchase common stock at an exercise price of $37.40 on substantially identical terms; provided, however that the warrants to the placement agent expired on December 19, 2012. At December 31, 2013, 112,500 of the warrants issued in this transaction remain outstanding.
	On October 15, 2009, we sold an aggregate of 230,769 shares of our common stock and 150,000 warrants to common stock to certain institutional investors in exchange for gross proceeds of $5.6 million, net of issuance costs. Each investor received warrants to purchase a number of shares equal to 75% of the number of shares of common stock purchased by the investor in the offering. The units were sold at a price of $26.00 per unit. The exercise price of the warrants is $28.00. In addition, the placement agent for the October financing received 11,538 warrants to purchase common stock at an exercise price of $32.60 on substantially identical terms; provided, however that the warrants to the placement agent expired on December 19, 2012. At December 31, 2013, 150,000 of the warrants issued in this transaction remain outstanding.
	On March 12, 2010, we completed a registered direct offering of 2,266,998 units, which were sold to institutional and retail investors, at a price of $5.00 per unit. The offering resulted in gross proceeds to us of $11.3 million and net proceeds of approximately $10.4 million after payment of offering fees and expenses. Each unit consisted of .5 share of common stock and a warrant to purchase .25 share of common stock. In the aggregate 1,133,500 shares of common stock and warrants to purchase an additional 566,750 shares of common stock were issued in the offering. Dawson James received placement agent fees of $793,449 and a warrant to purchase an aggregate of 56,675 shares of common stock, exercisable at $12.80 per share. The placement agent’s warrants expired on December 9, 2012. At December 31, 2013, 566,750 of the warrants issued in this transaction remain outstanding.
	On August 9, 2010 we filed a Form S-3 Registration Statement (declared effective by the securities and Exchange Commission on August 27, 2010) putting in place a universal shelf registration statement covering up to $50 million of any combination of common stock, preferred stock, debt securities, warrants, or units we may offer through August 9, 2013, at which time we will provide the specific term of any offering in one or more supplements to the prospectus. This registration statement is intended to allow us to capitalize on strategic opportunities that may arise; we do not have any current commitments for shares to be registered under the registration. The registration statement replaced an existing universal shelf registration statement that expired.
	On September 28, 2010, we entered into a Sales Agreement (“Sales Agreement”) with Brinson Patrick Securities Corporation to enable us to use Brinson Patrick as a sales manager to sell shares of our common stock from time to time in “at-the-market” transactions pursuant to our shelf registration statement on a best efforts basis. For the year ended December 31, 2011 we sold 524,393 shares under this agreement for net proceeds of $4,530,129.
	On November 17, 2010 we entered into a custom technology access and product license agreement with BioZone Laboratories, Inc. (“BioZone’) for the co-development and strategic licensing of a portfolio of up to 20 aesthetics, advanced skin care formulations and other products for our MedPodiumTM product line. The agreement grants us a royalty-free license of BioZone technology to develop a portfolio of 20 products, customized to our product specifications. and exclusive rights to the products developed to its specifications. The license is for a term of 10 years plus a one year automatic renewal. In exchange for the technology access license we paid BioZone a fee of $1.0 million. The license fee was paid with 100,000 shares of our unregistered common stock at a fair value $10.00 per share.
	On December 2, 2010 we filed a Tender Offer Statement to exchange (the “Warrant Exchange”) certain outstanding warrants dated March 9, 2007, November 5, 2008 and November 10, 2008 that contain unlimited “down round” price protection (the “Eligible Warrants”). The Eligible Warrants were exchanged for shares of our common stock, par value $0.0001. The Warrant Exchange expired at 9:00 p.m., Pacific Time, on December 30, 2010. Pursuant to the Warrant Exchange, an aggregate of 346,590 Eligible Warrants to purchase common stock were tendered and accepted for cancellation, representing approximately 67.49% of the total Eligible Warrants outstanding and eligible for exchange in the Warrant Exchange. On December 31, 2010, we issued an aggregate of 115,530 shares of our common stock in exchange for the eligible warrants surrendered in the Warrant Exchange. The gain on sale was calculated by taking the current fair value of the warrants, $1,419,761 and reducing this by the current market value of the shares issued of $901,139, resulting in a gain of $518,622. This gain was then reduced by a facilitation fee paid to Empire Asset Management in the amount of $44,750.
	On December 20, 2011 we made a $0.75 million equity investment in the form of unregistered, restricted Cardium shares to acquire rights to a 15% ownership interest in SourceOne Global Partners. Our ownership interest was acquired through the issuance into escrow of 75,000, shares of our common stock based on a $10.00 per share value representing a 70% premium above the closing price of our stock on December 19, 2011. We also have certain rights to maintain our proportionate ownership interest in SourceOne, and a right of first refusal to acquire SourceOne on the terms that SourceOne were to offer a third-party acquirer.
	In parallel with the cross-equity investment and acquisition of an ownership interest in SourceOne, we also received a license for a portfolio of nutraceutical, pharmaceutical and medical food product opportunities for a licensing fee of $0.75 million, which SourceOne applied to the purchase of 75,000 restricted shares of our common stock at $10.00 per share.
	During 2012, we raised net proceeds of $6.4 million through the completion of a registered direct equity financing with three institutional and accredited investors of 895,000 shares of Cardium common stock priced at $5.60 per share with no warrant coverage for net proceeds of approximately $4.5 million and through the sale of 260,000 shares of common stock under at-the-market transactions for net proceeds of $1.9 million.
	During the first quarter of 2013, we raised net proceeds of $65,743 through the sale of 17,187 shares of common stock under at-the-market transactions under our sales agreement with Brinson Patrick Securities Corporation.
	Preferred Stock
	In April 2013, we entered into a securities purchase agreement with one of our institutional investors pursuant to which we agreed to sell to the investor an aggregate of 4,012 shares of our newly authorized Series A Convertible Preferred Stock, for a total purchase price of $4.0 million. No warrants were issued in connection with this offering, other than 44,087 placement agent warrants with an exercise price of $2.275 per share and an expiration date of August 27, 2015. The securities purchase agreement provided for the sale of Series A Convertible Preferred Stock in two closings. The initial closing under the securities purchase agreement took place in April 2013, at which we sold 2,356 shares of Series A Convertible Preferred Stock for aggregate net proceeds of $2,160,000. A second closing for the remaining 1,656 shares of Series A Convertible Preferred Stock for aggregate net proceeds of $1,532,000 took place promptly after shareholder approval of the offering of the Series A Convertible Preferred Stock and the 1 for 20 reverse stock split of our outstanding common stock. That closing took place on July 18, 2013. Prior to December 31, 2013 the investor had converted 2,512 shares of Series A Convertible Preferred Stock into 2,332,851 shares of common stock. As a result of the conversion, 1,500 shares of Series A Convertible Preferred Stock were outstanding at December 31, 2013.
	The holders of our Series A Convertible Preferred Stock are entitled, on an as-converted basis, to dividends equal to and in the same form as any dividends declared and issued on our common stock. Except as required by law, holders of Series A Convertible Preferred Stock are not entitled to voting rights. Upon any liquidation, dissolution or winding up, holders of the Series A Convertible Preferred Stock will be entitled to a liquidation preference above the holders of common stock or any other junior stock in an amount equal to the original purchase price of $1,000, plus any fees, damages or dividends arising. The Series A Convertible Preferred Stock is convertible into shares of our common stock at the option of the holder, subject to a beneficial ownership limitation of 9.99%. The initial conversion price was $1.82 per share after giving effect to the reverse stock split, but was subsequently reset to $1.02 per share; the conversion price is subject to downward adjustment if we issue common stock or common stock equivalents at a price less than the then effective conversion price. We have the right to force conversion if the volume weighted average price for our common stock exceeds $12.00 per share for 25 trading days during a 30 consecutive trading day period and certain other equity conditions are met.
	As long as any shares of Series A Convertible Preferred Stock are outstanding, we have agreed that we will not, without the consent of the holders of two-thirds of the Series A Convertible Preferred Stock, incur indebtedness other than specified “Permitted Indebtedness”, incur any liens other than specified “Permitted Liens”, amend our Certificate of Incorporation in any manner that adversely affects the Series A Convertible Preferred Stock, repurchase or redeem any common stock or common stock equivalents, pay dividends on our common stock, or enter into any related party transactions.
	In connection with the convertible preferred stock, the Company determined the instrument contained a beneficial conversion feature at the date of issuance. This beneficial conversion feature amounted to $233,011 for the April transaction and was recorded as a deemed preferred dividend in April 2013. The beneficial conversion feature on the July transaction amounted to $172,861 and was recorded as a deemed preferred dividend in July 2013.
	Stockholder Rights Plan
	On July 10, 2006, our Board of Directors approved the adoption of a Stockholder Rights Plan (“Rights Plan”). Pursuant to the Rights Plan, we issued a dividend of one right for each share of our common stock held by stockholders of record as of the close of business on July 21, 2006. The rights are not immediately exercisable and will become exercisable only upon the occurrence of certain events. In general, if a person or group acquires, or announces a tender or exchange offer that would result in the acquisition of, 15% or more of our common stock while the Rights Plan remains in place, then, unless our Board of Directors elects to redeem the rights for $0.001 per right, the rights will become exercisable by all rights holders except the acquiring person or group, for 0.001 of a share of newly created Series A Junior Participating Preferred Stock at an exercise price of $40.00. Until the rights become exercisable, the rights are represented by, and automatically trade with, our common stock certificates.
	The Rights Plan was reviewed in 2012 and will be evaluated every three years by a committee of independent directors of our Board of Directors to consider whether the plan continues to be in the best interests of Cardium and its stockholders. The Rights Plan may be amended or revoked by our Board of Directors at any time and unless earlier terminated or amended, the rights will expire on July 10, 2016.
	Stock Options and Other Equity Compensation Plans
	We have an equity incentive plan that was established in 2005 under which 283,292 shares of our common stock have been reserved for issuance to employees, non-employee directors and consultants of the Company.
	At December 31, 2013 the following shares were outstanding and available for future issuance:
	Plan	Shares Outstanding			Shares Available
					for Issuance
	2005 Equity Incentive Plan		144,000			139,058
	There were no new grants during the year ended December 31, 2013. The following table summarizes the stock options and warrants that we granted during the year ended December 31, 2012:
	Grant	Quantity			Expected		Strike Price		Volatility			Dividend			Risk-Free			Grant Date		Aggregate
	Date	Issued			Life (Years)							Yield			Interest			Fair Value		Fair Value
															Rate			Per Option
	3/12/12		2,500			4.58	$	14.8		99	%		0	%		0.85	%	$	0.16	$	8,000
	11/5/12		2,500			4.4	$	14.8		98	%		0	%		0.64	%	$	0.09	$	4,500
	As of December 31, 2013, we had no unvested stock-based compensation at fair value remaining to be expensed. During the year ended December 31, 2013 we recognized $40,750 of stock option compensation expense.
	We calculate the fair value of stock options using the Black-Scholes option-pricing model. In determining the expected term, we separate groups of employees that have historically exhibited similar behavior with regard to option exercises and post-vesting cancellations. The option-pricing model requires the input of subjective assumptions, such as those included in the table above. The volatility rates are based principally on our historical stock prices and expectations of the future volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The total expense to be recorded in future periods will depend on several variables, including the number of share-based awards and expected vesting.
	The following is a summary of stock option and warrant activity under our equity incentive plan and warrants issued outside of the plan to employees and consultants, during the years ended December 31, 2013 and 2012:
		Number of			Weighted		Weighted
		Options or			Average		Average
		Warrants			Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2011		179,234		$	33.4		3.8
	Granted		5,000		$	14.8		4.5
	Exercised
	Cancelled		(2,500	)	$	14.8		0
	Cancelled (unvested)		(3,984	)	$	18.8		0
Expired (vested)
Balance outstanding, December 31, 2012		177,750		$	33.4		2.8
Granted		0		$	0		0
Exercised
Cancelled (unvested)		(2,844	)	$	14.8		0
Expired (vested)		(30,906	)	$	41.7		0
Balance outstanding, December 31, 2013		144,000		$	31.74		2.1
Balance exercisable, December 31, 2013		144,000		$	31.8		2.1
As of December 31, 2013 there was no intrinsic value to the outstanding and exercisable options.
Warrants
The following table summarizes warrant activity for the years ended December 31, 2013 and 2012:
	Number of			Weighted		Weighted
	Warrants			Average		Average
				Exercise		Remaining
				Price		Contractual
						Life
						(in years)
Balance outstanding, December 31, 2011		1,582,492		$	20.4		3.8
Warrants issued
Warrants exercised		(137	)	$	5.6
Warrants expired		(213,034	)	$	19.8
Warrants cancelled
Balance outstanding, December 31, 2012		1,369,321		$	19		2.1
Warrants issued		44,088			2.28
Warrants exercised		(0	)	$	0
Warrants expired		(434,579	)	$	15.72
Warrants cancelled
Balance outstanding, December 31, 2013		978,830		$	19.82		1.9
Warrants exercisable at December 31, 2013		978,830		$	19.82		1.9
As of December 31, 2013 there was no intrinsic value to the outstanding and exercisable options.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	Note 11—Segment Information
	Effective October 1, 2012, we commenced reporting the results our operations in two segments; Pharmaceutical Products and Health Sciences (“Nutraceutical”) Products. We established these two segments following our acquisition of To Go Brands, which presented us with a turn-key opportunity to acquire a limited but established portfolio of nutritional supplement products. We managed these two segments separately due to inherent differences in the nature of pharmaceutical and nutraceutical products. Pharmaceutical products are subject to significantly more stringent regulatory approval standards than nutraceutical products; there are material differences in the cost, time and effort we must expend to develop and test pharmaceutical products, each of these product categories have distinctly different marketing channels and the initial sales ramp is much slower for our products in the Pharmaceutical segment.
	The Nutraceutical segment of our business included the purchasing, packaging, selling and distribution of the To Go Brands portfolio of products that we acquired on September 28, 2012. The Pharmaceutical segment of our business, which is our core and planned principal operation, includes the development, testing and clinical trials of Generx and Excellagen products. The Company does not have an internal sales force for its pharmaceutical products and will rely on strategic partnerships and distribution agreements in the U.S. and internationally. We have distributed samples and made initial sales of Excellagen and have entered into distribution agreements for future sales growth. With the sale of our To Go Brands business as described in Note 3 we no longer have the Nutraceutical segment and therefore only have one reporting segment. Currently LifeAgain’s expenditures are immaterial and therefore doesn’t warrant a separate segment.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 12—Subsequent Events
	On February 28, 2014, the Company entered into a collaboration and financing arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd. (“Shanxi Taxus”), a strategic corporate investor based in China, pursuant to which the parties agreed to collaborate on the advancement of the Company’s product opportunities in China, and the investor’s product opportunities in the United States. The arrangement is reflected in two definitive agreements, each dated as of February 21, 2014, which were concluded and delivered on February 28, 2014, in connection with the first tranche of funding under the financing arrangement.
	Under the terms of a Collaboration Agreement, Shanxi Taxus agreed to apply commercially reasonable efforts to assist Cardium to develop and refine a plan or plans pursuant to which Cardium products, particularly its Generx ® and Excellagen ® product opportunities, could be commercialized in China; and Cardium agreed that it will, upon request, apply commercially reasonable efforts to assist Shanxi Taxus to develop and refine a plan or plans pursuant to which Shanxi Taxus’ oncology-related products and product opportunities could be commercialized in the United States. In connection with the collaboration agreement, the Company changed its name to Taxus Cardium Pharmaceuticals Group, Inc. In addition, the Company agreed that following the closing of $2.0 million in financing under the Stock Purchase Agreement (described below) it will increase the size of its board of directors by two members and appoint Mr. Jiayue Zhang, who is the Chairman of Shanxi Taxus, and an additional individual with U.S. corporate and financial experience to Cardium’s Board of Directors, and following the closing of $5.0 million of financing under the Stock Purchase Agreement, the Company will increase the size of its Board of Directors by one additional member and appoint a third individual designated by Shanxi Taxus to the Board of Directors.
	Under the terms of a Stock Purchase Agreement, Shanxi Taxus agreed to purchase up to $5 million of shares of the Company’s unregistered common stock in multiple tranches, each at a 10% premium to the then-current trailing average market prices of the Company’s common stock at the time of each closing.
	Cardium closed the initial tranche of funding by selling 714,286 shares of common stock at $0.70 per share, based on a trailing average price. The purchase price for each subsequent tranche would be equal to one hundred ten percent (110%) of the then-current volume-weighted average price for sales of the Company’s common stock over the thirty (30) calendar day period prior to each closing. Additional shares would be placed during an exclusive financing period ending on June 30, 2014, in up to four additional tranches, as follows: Tranche 2, in the amount One Million Five Hundred Thousand Dollars ($1,500,000) would be placed on or around March 31, 2014; Tranche 3, in the amount of One Million Dollars ($1,000,000) would be placed on or around April 30, 2014, provided that if the purchaser elected to not proceed with the full amount of Tranche 3, it would provide notice of such election to the Company on or before April 15, 2014, following which election, the amount of Tranche 3 would be reduced to a minimum of Three Hundred Thousand Dollars ($300,000), and the exclusive financing period with the purchaser would be terminated as of April 30, 2014; Tranche 4 , in the amount of One Million Dollars ($1,000,000) would be placed on or around May 30, 2014, provided that if the purchaser elected to not proceed with the full amount of Tranche 4, it would provide notice of such election to the Company on or before May 15, 2014, following which election, the amount of Tranche 4 would be reduced to a minimum of Three Hundred Thousand Dollars ($300,000), and the exclusive financing period would be terminated as of May 30, 2014; and Tranche 5 , in the amount of One Million Dollars ($1,000,000) would be placed on or around June 30, 2014, provided that if the purchaser elected to not proceed with the full amount of Tranche 5, it would provide notice of such election to the Company on or before June 16, 2014, following which election, the amount of Tranche 5 would be reduced to a minimum of Three Hundred Thousand Dollars ($300,000).
	The common stock purchased by the investor is unregistered but in the event that the Company files a registration statement for other shares of common stock after the exclusive financing period with the strategic investor ends, then the Company agreed to supplement such registration statement to provide “piggyback” registration rights for the shares purchased by the Shanxi Taxus. No warrants were issued to the strategic investor in connection with the transaction.
	On February 28, 2014 the Company issued 1,457,100 common stock warrants to directors, officers and our chief medical advisor. The warrants were approved by the Board of Directors, have a ten year term and an exercise price of $0.80 per share, which represents a 57% premium to the closing stock price on the date of issuance.
	The Company has evaluated events that occurred subsequent to December 31, 2013 and through the date the financial statements were issued.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements have been prepared in accordance with authoritative guidance for development stage enterprises.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, inventories, accounts payable, and accrued liabilities approximate fair value due to the short term maturities of these instruments.
Estimates	'
	Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include reserve for product returns, reserve for inventory, and valuing options and warrants using Option Pricing Models.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Taxus Cardium Pharmaceuticals Group, Inc. and its wholly-owned subsidiaries, Tissue Repair Company, To Go Brands, Inc. (a business that is presented as a discontinued operation as described in Note 3) and LifeAgain Insurance Solutions, Inc. (collectively, the “Company”). All significant inter-company transactions and balances have been eliminated in consolidation.
Business Acquisitions	'
	Business Acquisitions.
	Business combinations are accounted for using the acquisition method of accounting in accordance with ASC 850 “Business Combinations.” The cost of an acquisition is measured as the fair value of the consideration transferred on the acquisition date. When the Company acquires a business, it assesses the acquired assets and liabilities assumed for the appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions at the acquisition date. The excess of the total consideration transferred over the net identifiable assets acquired and liabilities assumed is recognized as goodwill. If this consideration is lower than the fair value of the identifiable net assets acquired, the difference is recognized as a gain on business acquisition. Acquisition costs are expensed as incurred and included in general and administrative expenses in our consolidated statements of operations.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject us to significant concentrations of credit risk consist of cash and cash equivalents. At times, our cash and cash equivalents may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. As of December 31, 2013, we had no cash and cash equivalent balances in excess of the federally insured limit of $250,000.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are stated at cost less an allowance for doubtful accounts, which reflects our estimate of balances that will be not collected. The allowance is based on the history of past write-offs, the aging of balances, collections experience and current credit conditions. Additions to the allowance for doubtful accounts include provisions for bad debt and deductions to the allowance for doubtful accounts including customer write-offs. The Company has a low occurrence of credit losses and therefore does not believe an allowance for doubtful accounts in necessary.
Inventory	'
	Inventory
	Inventories are stated at lower of cost or market and consist of raw materials associated with the Excellagen product. Inventories are valued on a first-in, first-out (FIFO) basis. The Company records reserves for inventories that are obsolete or exceed anticipated demand or carried at an amount that exceeds management’s estimate of net realizable. In establishing such reserves, management considers historical sales of identical and/or similar goods, product development plans and expected market demand.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost and include equipment, installation costs and materials. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the useful lives or the term of the respective lease.
	Expenditures for maintenance and repairs, which do not extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in general and administrative expenses in the statement of operations.
Technology Licenses	'
	Technology Licenses
	Technology licenses represent two distinct licenses that we acquired for the use of fully developed product formulas that we planned to use as part of our initiative to create a portfolio of nutraceutical products. We planned to market these products to consumers principally through convenience stores, pharmacy chains, and wholesale clubs that we gained access to as a result of our acquisition of To Go Brands (Note 3). These licenses were initially recorded at cost and were being amortized over the fixed term of the underlying agreements, which we believed was approximately equal to the useful lives of the underlying product formulas. We periodically tested the carrying amounts of these licenses for possible impairment in accordance with the guidelines enumerated under Accounting Standards Codification (“ASC”) 350 “Intangibles-Goodwill and Other.” Under ASC 350, intangible assets with definite lives are periodically tested for impairment based on an analysis of undiscounted cash flows (as described below). Management has determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and the write-off of the unamortized balance of $1.1 million of our technology licenses associated with that product line.
Long-Lived Assets	'
	Long-Lived Assets
	Long-lived assets to be held and used, including property, plant and equipment as well as intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable such as:
		•		a significant decline in the observable market value of an asset;
		•		a significant change in the extent or manner in which an asset is used; or
		•		a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.
	Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell. We do not believe there was any impairment of long-lived assets at December 31, 2013 but determined it appropriate to discontinue the nutraceutical operations which led to the sale of To Go Brands Inc., and to fully reserve the unamortized balance of $1.1 million of our technology licenses which was focused on that product line.
Preferred Stock	'
	Preferred Stock
	We apply the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of our preferred stock. Shares that are subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. We classify conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Revenue Recognition	'
	Revenue Recognition
	The Company’s revenues principally consist of sales of Excellagen product. The Company applies the revenue recognition principles set forth under the Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 104. Accordingly, revenue from product sales is recognized when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. These criteria are met when the risk of ownership and title passes to the Company’s customers.
Research and Development	'
	Research and Development
	In accordance with ASC Topic 730 research and development costs are expensed as incurred. Research and development expenses consist of purchased technology, purchased research and development rights and outside services for research and development activities associated with product development. In accordance with ASC Topic 730, the cost to purchase such technology and research and development rights are required to be charged to expense if there is currently no alternative future use for this technology and, therefore, no separate economic value.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not to be sustained upon examination.
Common Stock Purchase Warrants	'
	Common Stock Purchase Warrants
	We account for the issuance of common stock purchase warrants issued in connection with capital financing transactions in accordance with the provisions of ASC Topic 815. Based upon the provisions of ASC Topic 815, we classify as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). We classify as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).
Loss Per Common Share	'
	Loss Per Common Share
	We compute loss per share, in accordance with ASC Topic 260 which requires dual presentation of basic and diluted earnings per share.
	Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities were not included in the calculation of loss per common share for the years ended December 31, 2013 or 2012 because their effect would be anti-dilutive.
	As of December 31, 2013 potentially dilutive securities consist of outstanding stock options and warrants to acquire 1,122,830 shares of our common stock. As of December 31, 2012, potentially dilutive securities consisted of outstanding stock options and warrants to acquire 1,547,071 shares of our common stock.
Stock-Based Compensation	'
	Stock-Based Compensation
	Stock-based compensation costs are recognized on a straight-line basis over the requisite service period of the award, which is generally the vesting term of the award.
	Total stock-based compensation expense included in the consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
			December 31,
			2013		2012
	Research and development		$	5,997	$	23,883
	General and administrative			34,753		145,863
	Total stock-based compensation		$	40,750	$	169,746
Deferred Rent	'
	Deferred Rent
	Rent expense is recorded on the straight-line method based on the total minimum rent payments required over the term of the lease. The cumulative difference between the lease expense recorded under this method and the contractual lease payment terms is recorded as deferred rent.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	We do not believe that any recently issued accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses	'
	Total stock-based compensation expense included in the consolidated statements of operations was allocated to research and development and general and administrative expenses as follows:
		December 31,
		2013		2012
	Research and development	$	5,997	$	23,883
	General and administrative		34,753		145,863
	Total stock-based compensation	$	40,750	$	169,746

Disposal_of_LongLived_Assets_T

Disposal of Long-Lived Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations And Disposal Groups [Abstract]	'
Assets and Liabilities of Discontinued Operations	'
	Assets and liabilities of discontinued operations
	The major categories of assets and liabilities of discontinued operations included in the consolidated balance sheet at December 31, 2012 were as follows:
	Assets of discontinued operations:
	Accounts receivable		306,633
	Inventories, net		492,229
	Prepaid expenses and other current assets		53,684
	Property, plant and equipment, net		45,467
	Goodwill		584,711
	Intangibles, net		1,019,692
	Long term assets		9,028
	Total assets of discontinued operations	$	2,511,444
	Liabilities of discontinued operations:
	Accounts payable	$	403,735
	Accrued liabilities		238,345
	Total liabilities of discontinued operations	$	642,080
Summary of Financial Information for the Discontinued Operations Included in the Consolidated Statements of Operations	'
	The following results of operations of To Go Brands, Inc. and the expense associated with the write-off of the remaining recorded value of the technology licenses associated with the nutraceutical business are presented as a loss from a discontinued operation in the consolidated statements of operations:
		For the years  ended						Period from
		December 31,						December 22,
								2003
								(Inception) to
								December 31,
		2013			2012			2009
	Revenues
	Product sales	$	1,728,177		$	725,909		$	2,454,086
	Cost of goods sold		1,002,064			382,914			1,384,978
	Gross profit		726,113			342,995			1,069,108
	Operating expenses
	Research and development		128,215			40,227			168,442
	Selling, general and administrative		1,507,210			398,761			1,905,971
	Total operating expenses		1,635,425			438,988			2,074,413
	Loss from operation		(909,312	)		(95,993	)		(1,005,305	)
	Interest, net		(667	)		(203	)		(870	)
	Net loss from discontinued operations of To Go Brands, Inc.	$	(909,979	)	$	(96,196	)	$	(1,006,175	)
	Write-off of technology licenses associated with the nutraceutical product lines		(1,097,511	)		0			(1,097,511	)
	Net loss from discontinued operations	$	(2,007,490	)	$	(96,196	)	$	(2,103,686	)
Net Assets Sold	'
	The following is the calculation of the net assets on the sale of To Go Brands, Inc.
	Net assets sold:
	Accounts receivable		106,843
	Prepaid expenses and other current assets		8,059
	Inventory, net		456,276
	Property and equipment, net		18,082
	Intangible assets, net		1,481,123
	Other long term assets		0
	Accounts payable		(305,072	)
	Other liabilities		(65,639	)
	Net Assets of To Go Brands, Inc. sold		1,699,672

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Summary of Inventories	'
	Inventories consisted of the following:
		December 31,			December 31,
		2013			2012
	Raw materials	$	183,398		$	430,825
	Finished goods		0			313,700
			183,398			744,525
	Less provision for obsolete inventory		(23,567	)		(62,431	)
	Inventories, net	$	159,831		$	682,094

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consisted of the following:
		December 31,
		2013			2012
	Computer and telecommunication equipment	$	425,331		$	532,069
	Machinery and equipment		31,779			31,779
	Office equipment		11,490			53,050
	Instrumentation		0			115,421
	Office furniture and equipment		223,206			480,594
	Leasehold improvements		23,053			152,774
			714,859			1,365,687
	Accumulated depreciation and amortization		(684,663	)		(1,313,572	)
	Property and equipment, net	$	30,196		$	52,115

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Summary of Accrued Liabilities	'
	Accrued Liabilities consisted of the following:
		December 31,
		2013		2012
	Payroll and benefits	$	511,098	$	376,512
	Other		99,909		0
	Total	$	611,007	$	376,512

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Future Annual Minimum Rental Payments under Leases	'
	Future annual minimum rental payments under the leases are as follows:
	Year Ending December 31,	Facilities
		(Operating Lease)
	2014		150,458
	2015		121,596
	2016		82,936
	Total	$	354,990

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Summary of Net Deferred Tax Asset	'
	Our net deferred tax asset consisted of the following at December 31, 2013 and 2012:
		December 31,
		2013			2012
	Deferred tax asset:
	Net operating loss carryforwards	$	36,837,171		$	35,135,946
	Deferred compensation		881,025			881,025
	Depreciation and amortization		886,149			944,369
	License impairment		437,187			0
	Deferred rent		0			20,065
	Research and development credit		194,132			0
	Accrued expenses		97,326			100,936
	Other		137,611			57,643
	Total deferred tax assets		39,470,601			37,139,984
	Less: Valuation allowance		(39,470,601	)		(37,139,984	)
	Net deferred tax asset		—			—
Summary of Income Tax Provision (Benefit) from Income Taxes	'
	The income tax provision (benefit) from income taxes consists of the following at December 31, 2013 and 2012:
		Years Ended December 31,
		2013			2012
	Federal
	Current	$			$
	Deferred		(1,306,714	)		(3,770,936	)
	State
	Current
	Deferred		(224,232	)		(646,426	)
	Total	$	(1,530,946	)	$	(4,417,362	)
	Change in valuation allowance		1,530,946			4,417,362
	Income tax provision (benefit)	$	—		$	—
Summary of Provision for Income Taxes Using Statutory Federal Tax Rate	'
	The provision for income taxes using the statutory federal tax rate as compared to our effective tax rate is summarized as follows:
		December 31,
		2013			2012
	Expected U.S. federal statutory rate		(34.0	)%		(34.0	)%
	State income taxes, net of federal benefit		(5.8	)%		(5.8	)%
	Deferred tax true-up		18.7	%		(13.5	)%
	R&D credit		(1.4	)%		0	%
	Other permanent differences		0.3	%		0.3	%
			(22.2	)%		(53.0	)%
	Change in valuation allowance		22.2	%		53	%
	Totals		0	%		0	%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Available Outstanding Shares for Future Issuance	'
	At December 31, 2013 the following shares were outstanding and available for future issuance:
	Plan	Shares Outstanding			Shares Available
					for Issuance
	2005 Equity Incentive Plan		144,000			139,058
Schedule of Granted Stock Options and Warrants	'
	The following table summarizes the stock options and warrants that we granted during the year ended December 31, 2012:
	Grant	Quantity			Expected		Strike Price		Volatility			Dividend			Risk-Free			Grant Date		Aggregate
	Date	Issued			Life (Years)							Yield			Interest			Fair Value		Fair Value
															Rate			Per Option
	3/12/12		2,500			4.58	$	14.8		99	%		0	%		0.85	%	$	0.16	$	8,000
	11/5/12		2,500			4.4	$	14.8		98	%		0	%		0.64	%	$	0.09	$	4,500
Summary of Stock Option Activity under Equity Incentive Plan and Warrants Issued Outside Plan	'
	The following is a summary of stock option and warrant activity under our equity incentive plan and warrants issued outside of the plan to employees and consultants, during the years ended December 31, 2013 and 2012:
		Number of			Weighted		Weighted
		Options or			Average		Average
		Warrants			Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2011		179,234		$	33.4		3.8
	Granted		5,000		$	14.8		4.5
	Exercised
	Cancelled		(2,500	)	$	14.8		0
	Cancelled (unvested)		(3,984	)	$	18.8		0
	Expired (vested)
	Balance outstanding, December 31, 2012		177,750		$	33.4		2.8
	Granted		0		$	0		0
	Exercised
	Cancelled (unvested)		(2,844	)	$	14.8		0
	Expired (vested)		(30,906	)	$	41.7		0
	Balance outstanding, December 31, 2013		144,000		$	31.74		2.1
	Balance exercisable, December 31, 2013		144,000		$	31.8		2.1
Summary of Warrant Activity	'
	The following table summarizes warrant activity for the years ended December 31, 2013 and 2012:
		Number of			Weighted		Weighted
		Warrants			Average		Average
					Exercise		Remaining
					Price		Contractual
							Life
							(in years)
	Balance outstanding, December 31, 2011		1,582,492		$	20.4		3.8
	Warrants issued
	Warrants exercised		(137	)	$	5.6
	Warrants expired		(213,034	)	$	19.8
	Warrants cancelled
	Balance outstanding, December 31, 2012		1,369,321		$	19		2.1
	Warrants issued		44,088			2.28
	Warrants exercised		(0	)	$	0
	Warrants expired		(434,579	)	$	15.72
	Warrants cancelled
	Balance outstanding, December 31, 2013		978,830		$	19.82		1.9
	Warrants exercisable at December 31, 2013		978,830		$	19.82		1.9

Organization_and_Liquidity_Add

Organization and Liquidity - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

120 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Nov. 15, 2013

Jul. 31, 2013

Jul. 17, 2013

Sep. 16, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Jul. 24, 2009

19-May-05

Dec. 31, 2003

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2014

Jan. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jul. 24, 2009

Transactions [Member]

Series A Preferred Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Schering AG Group [Member]

Tissue Repair Company [Member]

To Go Brands, Inc. [Member]

Innercool Therapies, Inc. [Member]

Innercool Therapies, Inc. [Member]

Transactions [Member]

Organization, Nature Of Operations And Liquidity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incorporation date

'

'

'

'

22-Dec-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Oct-05

31-Aug-06

28-Sep-12

31-Mar-06

'

Sales of assets and liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11,250,000

Trade payables

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

Percentage of preferred stock in fully-diluted common stock

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities assumed on sale of business

370,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

'

$0.00

'

$0.00

$0.00

'

$0.00

'

$0.00

'

'

'

$0.70

'

'

'

'

'

'

Stockholder's equity reverse stock split ratio

'

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares before split common stock outstanding

'

134,366,340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares after split common stock outstanding

'

6,718,317

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

22,489

2,328,074

4,721,279

22,489

'

'

0

'

'

'

'

'

'

'

'

'

Working capital deficit

'

'

'

'

1,110,000

'

'

1,110,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares issued

'

'

'

150,000

'

'

'

'

'

'

'

714,286

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

'

'

'

'

65,743

'

4,530,129

'

'

'

'

'

'

'

492,500

'

'

'

'

'

Net cash used in operating activities

'

'

'

'

-6,025,376

-9,212,565

'

-100,319,702

'

'

'

'

'

'

'

'

'

'

'

'

Net cash provided by financing activities

'

'

'

'

3,742,844

6,547,075

'

102,922,710

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

4,012

'

'

'

'

'

'

'

Common stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

Net proceeds from issuance of common stock

'

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net cash provided by (used in) investing activities

'

'

'

'

-23,053

272,285

'

-2,580,519

'

'

'

'

'

'

'

'

'

'

'

'

Capital expenditure

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Majority of shareholders' consent to incur indebtedness other than specified permitted indebtedness

'

'

'

'

'Two-thirds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 20, 2011	Nov. 17, 2010	Dec. 31, 2003
	License
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Cash and cash equivalents excess of FDIC insured amount	$22,489	$2,328,074	$4,721,279	'	'	$0
Cash and cash equivalents FDIC insured amount	250,000	'	'	'	'	'
Number of technology licenses	0	'	'	'	'	'
Write-off of the unamortized balance	1,100,000	'	'	'	'	'
Impairment of long-lived assets	0	'	'	'	'	'
Unamortized balance of technology licenses	1,100,000	'	'	358,875	738,636	'
Dilutive securities not included in calculation of loss per common share	0	0	'	'	'	'
Outstanding stock options and warrants	1,122,830	1,547,071	'	'	'	'
Credit Concentration Risk [Member]	'	'	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Cash and cash equivalents excess of FDIC insured amount	$0	'	'	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Allocated to Research, Development, General and Administrative Expenses (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	$40,750	$169,746
Research and Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	5,997	23,883
General and Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation	$34,753	$145,863

Disposal_of_LongLived_Assets_A

Disposal of Long-Lived Assets - Assets and Liabilities of Discontinued Operations (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Liabilities of discontinued operations	'	'
Total liabilities of discontinued operations	$0	$642,080
To Go Brands, Inc. [Member]	'	'
Assets of discontinued operations	'	'
Accounts receivable	'	306,633
Inventories, net	'	492,229
Prepaid expenses and other current assets	'	53,684
Property, plant and equipment, net	'	45,467
Goodwill	'	584,711
Intangibles, net	'	1,019,692
Long term assets	'	9,028
Total assets of discontinued operations	'	2,511,444
Liabilities of discontinued operations	'	'
Accounts payable	'	403,735
Accrued liabilities	'	238,345
Total liabilities of discontinued operations	'	$642,080

Disposal_of_LongLived_Assets_S

Disposal of Long-Lived Assets - Summary of Financial Information for the Discontinued Operations Included in the Consolidated Statements of Operations (Detail) (USD $)	12 Months Ended		120 Months Ended	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009
				To Go Brands, Inc. [Member]	To Go Brands, Inc. [Member]	To Go Brands, Inc. [Member]
Revenues	'	'	'	'	'	'
Product sales	'	'	'	$1,728,177	$725,909	$2,454,086
Cost of goods sold	'	'	'	1,002,064	382,914	1,384,978
Gross profit	'	'	'	726,113	342,995	1,069,108
Operating expenses	'	'	'	'	'	'
Research and development	'	'	'	128,215	40,227	168,442
Selling, general and administrative	'	'	'	1,507,210	398,761	1,905,971
Total operating expenses	'	'	'	1,635,425	438,988	2,074,413
Loss from operation	'	'	'	-909,312	-95,993	-1,005,305
Interest, net	'	'	'	-667	-203	-870
Net loss from discontinued operations of To Go Brands, Inc.	'	'	'	-909,979	-96,196	-1,006,175
Write-off of technology licenses associated with the nutraceutical product lines	-1,097,511	0	-1,097,511	-1,097,511	0	-1,097,511
Net loss from discontinued operations	($2,007,490)	($96,196)	($24,568,710)	($2,007,490)	($96,196)	($2,103,686)

Disposal_of_LongLived_Assets_A1

Disposal of Long-Lived Assets - Additional Information (Detail)	0 Months Ended	12 Months Ended
	Nov. 15, 2013	Dec. 31, 2013
		Cell-nique [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Selling price	33,441	'
Fully-diluted voting interests percentage	'	4.00%
Accrue dividend percentage	'	8.00%

Disposal_of_LongLived_Assets_N

Disposal of Long-Lived Assets - Net Assets Sold (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Net assets sold:	'	'
Accounts receivable	$0	$22,320
Prepaid expenses and other current assets	309,200	403,705
Inventory, net	159,831	682,094
Property and equipment, net	30,196	52,115
Other long term assets	129,989	175,808
Accounts payable	-990,279	-374,126
To Go Brands, Inc. [Member] | Discontinued Operations [Member]	'	'
Net assets sold:	'	'
Accounts receivable	106,843	'
Prepaid expenses and other current assets	8,059	'
Inventory, net	456,276	'
Property and equipment, net	18,082	'
Intangible assets, net	1,481,123	'
Other long term assets	0	'
Accounts payable	-305,072	'
Other liabilities	-65,639	'
Net Assets of To Go Brands, Inc. sold	$1,699,672	'

Inventories_Summary_of_Invento

Inventories - Summary of Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory, Net [Abstract]	'	'
Raw materials	$183,398	$430,825
Finished goods	0	313,700
Inventories, gross	183,398	744,525
Less provision for obsolete inventory	-23,567	-62,431
Inventories, net	$159,831	$682,094

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$714,859	$1,365,687
Accumulated depreciation and amortization	-684,663	-1,313,572
Property and equipment, net	30,196	52,115
Computer and Telecommunication Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	425,331	532,069
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	31,779	31,779
Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	11,490	53,050
Instrumentation [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	0	115,421
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	223,206	480,594
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$23,053	$152,774

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended		120 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'	'	'
Depreciation and amortization of property and equipment from continuing operations	$44,973	$99,332	$1,414,271

Recovered_Sheet1

Intangible Assets and Strategic Investment - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Dec. 20, 2011	Nov. 17, 2010	Dec. 31, 2013	Dec. 31, 2012	Sep. 16, 2009
		Product_Lines
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Number of aesthetics product in portfolio	'	20	'	'	'
License agreement, renewal period	'	'1 year	'	'	'
Unamortized balance of technology licenses	$358,875	$738,636	$1,100,000	'	'
License agreement, closing price	'	'	'	'	$30
Exercise fee	10,000	'	'	'	'
Number of allotments held in escrow option	'	'	'Four allotments at 6, 9, 12 and 18 months following the closing date	'	'
Option held in escrow allotment 1	'6 months	'	'	'	'
Option held in escrow allotment 2	'9 months	'	'	'	'
Option held in escrow allotment 3	'12 months	'	'	'	'
Option held in escrow allotment 4	'18 months	'	'	'	'
Shares released from the escrow account	'	'	25,000	50,000	'
Option term period	'	'	'7 years	'	'
Option remaining exercise period	'	'	'5 years	'	'
Licensing Agreements [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License agreement, term	'	'10 years	'	'	'
License agreement, closing price	$5.80	'	'	'	'
Licensing Agreements [Member] | Restricted Stock [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License agreement, closing price	$5.80	'	'	'	'
License Fee [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License fee paid in shares	'	100,000	'	'	'
License Fee [Member] | Restricted Stock [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License fee paid in shares	75,000	'	'	'	'
BioZone Laboratories, Inc. [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License costs	'	$1,000,000	'	'	'
BioZone Laboratories, Inc. [Member] | License Fee [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License fee, amortization period	'	'11 years	'	'	'
SourceOne Global Partners, LLC [Member] | Restricted Stock [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License agreement, closing price	$10	'	'	'	'
SourceOne Global Partners, LLC [Member] | License Fee [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
License fee, amortization period	'10 years	'	'	'	'
License agreement, escrow shares	75,000	'	'	'	'
License fee, equity investment	15.00%	'	'	'	'

Accrued_Liabilities_Summary_of

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued Liabilities Current [Abstract]	'	'
Payroll and benefits	$511,098	$376,512
Other	99,909	0
Total	$611,007	$376,512

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended				0 Months Ended		12 Months Ended
	Aug. 15, 2013	Oct. 31, 2005	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jan. 30, 2013	Sep. 28, 2012	Dec. 31, 2013
	sqft						To Go Brands, Inc. [Member]	To Go Brands, Inc. [Member]	To Go Brands, Inc. [Member]
							sqft	sqft
Commitments And Contingencies Disclosure [Line Items]	'	'	'	'	'	'	'	'	'
Area under lease	4,419	'	'	'	'	'	2,471	4,745	'
Lease term	'	'	'	'	'	'	'	'2 years	'
Lease base rent payment	$9,678	'	'	'	'	'	$1,853	$4,270	'
Lease rent payment for second year	10,016	'	'	'	'	'	'	'	4,441
Association monthly fees	'	'	'	'	'	'	'	'	300
Security deposit	9,231	'	'	'	'	'	1,853	'	4,441
Term of lease period from lease commencement date	'36 months	'	'	'	'	'	'	'	'
Lease rent payment for third year	10,367	'	'	'	'	'	'	'	'
Rent expense in continuing operations	'	'	435,573	582,146	'	'	'	'	'
Technology transaction fees	'	4,000,000	'	'	'	'	'	'	'
Milestone payment required as a sale of product	'	10,000,000	'	'	'	'	'	'	'
Future royalty percentage on net sales	'	5.00%	'	'	'	'	'	'	'
Royalties to net sales of other product	'	4.00%	'	'	'	'	'	'	'
Agreement amended canceled notice period	'	'60 days	'	'	'	'	'	'	'
Annual royalty fee under agreement	'	2.00%	'	'	'	'	'	'	'
Minimum annual royalty fee current	'	'	'	'	'	100,000	'	'	'
Minimum annual royalty fee current in two years	'	'	'	'	100,000	'	'	'	'
Minimum annual royalty fee current in three years	'	'	'	150,000	'	'	'	'	'
Minimum annual royalty fee current in four years	'	'	150,000	'	'	'	'	'	'
Minimum annual royalty fee current in five years	'	'	$200,000	'	'	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Future Annual Minimum Rental Payments under Leases (Detail) (USD $)	Dec. 31, 2013
Operating Leases Future Minimum Payments Due [Abstract]	'
2014	$150,458
2015	121,596
2016	82,936
Total	$354,990

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Liability for unrecognized tax benefits	$0	$0
Interest and penalties related to unrecognized tax benefits	0	0
Net operating loss carryovers	92,500,000	88,200,000
Net operating loss maturity date	'2023	'
State income tax maturity date	'2013	'
Change in valuation allowance	1,530,946	4,417,362
Income tax benefit	$0	$0

Income_Taxes_Summary_of_Net_De

Income Taxes - Summary of Net Deferred Tax Asset (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax asset:	'	'
Net operating loss carryforwards	$36,837,171	$35,135,946
Deferred compensation	881,025	881,025
Depreciation and amortization	886,149	944,369
License impairment	437,187	0
Deferred rent	0	20,065
Research and development credit	194,132	0
Accrued expenses	97,326	100,936
Other	137,611	57,643
Total deferred tax assets	39,470,601	37,139,984
Less: Valuation allowance	-39,470,601	-37,139,984
Net deferred tax asset	'	'

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Tax Provision (Benefit) from Income Taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Federal	'	'
Current	'	'
Deferred	-1,306,714	-3,770,936
State	'	'
Current	'	'
Deferred	-224,232	-646,426
Total	-1,530,946	-4,417,362
Change in valuation allowance	1,530,946	4,417,362
Income tax provision (benefit)	$0	$0

Income_Taxes_Summary_of_Provis

Income Taxes - Summary of Provision for Income Taxes Using Statutory Federal Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Expected U.S. federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal benefit	-5.80%	-5.80%
Deferred tax true-up	18.70%	-13.50%
R&D credit	-1.40%	0.00%
Other permanent differences	0.30%	0.30%
Provision for Income Tax, Gross	-22.20%	-53.00%
Change in valuation allowance	22.20%	53.00%
Totals	0.00%	0.00%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

108 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Sep. 16, 2009

Mar. 09, 2007

Apr. 01, 2005

Dec. 31, 2003

Dec. 31, 2013

Dec. 31, 2013

Jul. 17, 2013

Dec. 31, 2012

Mar. 12, 2010

Oct. 20, 2005

19-May-05

Mar. 09, 2007

Dec. 31, 2013

Oct. 20, 2005

Dec. 31, 2013

20-May-05

Apr. 01, 2005

Apr. 01, 2005

Jul. 01, 2005

Private Placement [Member]

Private Placement [Member]

Aries Venture Incorporation [Member]

Shareholders of Acquiree [Member]

Co-Founder [Member]

Co-Founder [Member]

Co-venturer [Member]

Undivided Interest [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of incorporation

'

'

'

'

22-Dec-03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares sold to founders and executives

'

'

190,000

85,000

'

'

'

'

'

'

'

'

'

'

'

17,500

182,500

'

100,000

Common stock value sold to founders and executives

'

'

'

$17,000

'

'

'

'

'

'

'

'

'

'

'

$3,500

'

$38,000

$20,000

Authorized shares of common stock

'

'

'

'

200,000,000

200,000,000

'

200,000,000

'

'

5,500,000

'

'

'

'

'

'

'

'

Additional number of common stock authorized

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

Common stock initial par value before amendment in capital structure

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

Par value of common stock shares against which warrants are exchanged

'

'

'

'

$0.00

$0.00

$0.00

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

Common stock outstanding number of shares at the time of reverse merger

'

'

'

'

8,810,624

8,810,624

'

6,460,586

'

392,500

'

'

'

101,611

'

'

'

'

'

Warrant exercise period

'

'

'

'

'

'3 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Warrants to purchase shares of common stock

'

'

'

'

'

'

'

'

0.25

'

'

151,130

21,213

'

20,000

'

'

'

'

Percentage of shares outstanding held by minority share holders before reverse merger and acquisition

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

45.00%

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

75

35

'

35

'

'

'

'

Warrant held by share holders of Aries Venture Inc Warrants expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'2008-10

'

'2008-10

'

'

'

'

Registered direct offering of common stock

150,000

'

'

'

'

'

'

'

'

'

'

431,800

966,282

'

'

'

'

'

'

Purchase price of common stock under first registered direct offering

$30

'

'

'

'

'

'

'

'

'

'

$50

$30

'

'

'

'

'

'

Net proceed from issuance of stock in private placements

'

$20,000,000

'

'

'

'

'

'

'

'

'

'

$25,542,389

'

'

'

'

'

'

Minimum number of shares to be hold to receive right of warrant

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

Maximum percentage of common stock acquired in private placement to be issued on exercise of warrant

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

Stockholders_Equity_Additional1

Stockholders' Equity - Additional Information 1 (Detail) (USD $)	0 Months Ended		108 Months Ended			0 Months Ended	12 Months Ended	0 Months Ended
	Sep. 16, 2009	Mar. 09, 2007	Dec. 31, 2013	Mar. 12, 2010	Nov. 30, 2007	Mar. 09, 2007	Dec. 31, 2013	Mar. 08, 2006
					Life Sciences Capital Llc [Member]	Private Placement [Member]	Private Placement [Member]	Innercool Therapies, Inc. [Member]
Stockholders Equity [Line Items]	'	'	'	'	'	'	'	'
Common stock issued to Innercool Therapies Inc	'	'	'	'	'	'	'	125,000
Registered direct offering of common stock	150,000	'	'	'	'	431,800	966,282	'
Purchase price of common stock under first registered direct offering	$30	'	'	'	'	$50	$30	'
Percentage of shares outstanding held by minority share holders before reverse merger and acquisition	'	'	'	'	'	35.00%	'	'
Warrants exercise price	'	'	'	'	75	75	35	'
Warrants to purchase shares of common stock	'	'	'	0.25	4,666	151,130	21,213	'
Triggering date of warrants as per price protection provision	'	'	'	'	'	31-Jan-08	'	'
Reduced exercise price of warrant	'	'	'	'	'	$40	'	'
Net proceed from issuance of stock in private placements	'	$20,000,000	'	'	'	'	$25,542,389	'
Selling commissions and expense incurred for shares issued in private placement	'	'	'	'	'	'	1,480,300	'
Legal, accounting and other fees and expenses incurred for shares issued in private placement	'	'	'	'	'	'	100,000	'
Warrant exercise period	'	'	'3 years	'	'	'	'5 years	'
Warrants issue to placement agent	'	'	'	'	'	'	25,908	'
Exercise price of warrant issuable on exercise of warrant to placement agent	'	'	'	'	'	'	$75.60	'
Debt financing principal amount	'	'	'	'	5,000,000	'	'	'
Deferred financing costs	'	'	'	'	$108,500	'	'	'

Stockholders_Equity_Additional2

Stockholders' Equity - Additional Information 2 (Detail) (USD $)

0 Months Ended

12 Months Ended

120 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Mar. 12, 2010

Sep. 16, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Nov. 05, 2008

Nov. 05, 2008

Mar. 05, 2009

Jun. 23, 2009

Mar. 12, 2010

Oct. 15, 2009

Dec. 31, 2013

Dec. 31, 2012

Nov. 05, 2008

Mar. 05, 2009

Jun. 23, 2009

Mar. 05, 2009

Jan. 31, 2008

Dec. 31, 2012

Jun. 27, 2008

Jun. 23, 2009

Jun. 27, 2008

Jun. 27, 2008

Jun. 27, 2008

Jun. 27, 2008

Jun. 27, 2008

Jun. 27, 2008

Jul. 18, 2008

Jul. 18, 2008

Jul. 18, 2008

Jul. 18, 2008

Jul. 18, 2008

Jul. 18, 2008

Warrants Exercise Price Two [Member]

Secured Debt [Member]

Senior Subordinated Secured Debt [Member]

Unsecured Debt [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Senior Subordinated Loans [Member]

Registered Direct Offering [Member]

Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Second Follow On Registered Direct Offering [Member]

Senior Subordinated Secured Debt [Member]

Unsecured Debt [Member]

Common Stock [Member]

Common Stock [Member]

Warrants Exercise Price One [Member]

Warrants Exercise Price One [Member]

Warrants Exercise Price Two [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Public Offering [Member]

Warrants Exercise Price One [Member]

Warrants Exercise Price Two [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrants Exercise Price One [Member]

Warrants Exercise Price Two [Member]

Warrants Exercise Price One [Member]

Warrants Exercise Price Two [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registered direct offering of common stock

'

150,000

'

'

'

'

'

'

'

'

1,133,500

230,769

17,187

1,151,487

'

'

'

'

132,750

'

'

'

'

'

81,250

'

'

'

'

'

'

83,500

'

'

Purchase price of common stock under first registered direct offering

'

$30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$40

'

'

'

'

'

$40

'

'

'

'

'

'

$40

'

'

Proceeds from issuance of common stock

'

'

$65,743

'

$4,530,129

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,300,000

'

'

'

'

'

'

'

'

$3,250,000

'

'

'

$3,340,000

'

'

Placement agent fees and offering expenses under registered direct offering

'

'

67,386

67,386

'

67,386

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

224,000

'

'

'

'

'

'

330,000

'

'

Warrants to purchase shares of common stock

0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

469,331

75,250

25,125

'

'

51,428

'

'

'

'

118,575

113,750

4,825

'

'

'

'

121,450

116,900

4,550

Warrants exercise price

'

'

'

'

'

'

'

40

40

40

'

'

'

'

'

'

'

'

40

'

'

10

10

45.8

'

'

'

'

'

10

44

'

'

'

Warrants expiration period under registered direct offering

'

'

'

'

'

'

'2013-11

'

'

'

'

'

'

'

'

'

'

'

'2013-01

'

'2013-06

'

'

'

'

'

'

'

'2013-06

'

'

'

'

'

Principle amount of notes issued

'

'

0

0

'

500,000

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants contractual term under Registered direct offering

'

'

'

'

'

'

'

'5 years

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior subordinated secured debt

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds received before placement agent fees and offering expenses of subordinated secured debt

'

'

'

'

'

'

'

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement agent fees and Offering expenses

793,449

'

871,833

871,833

'

871,833

'

'

'

50,000

'

'

'

'

'

'

'

252,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant to purchase unit

'

'

'

'

'

'

'

'

'

603

'

'

'

'

'

'

'

4,515

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured debt financing with accompanying warrants

'

'

'

'

'

'

'

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate gross proceeds before expenses and fees

'

'

'

'

'

'

'

'

'

$750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Additional3

Stockholders' Equity - Additional Information 3 (Detail) (USD $)

0 Months Ended

12 Months Ended

120 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

Mar. 12, 2010

Oct. 15, 2009

Sep. 16, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Aug. 09, 2010

Sep. 16, 2009

Mar. 12, 2010

Oct. 15, 2009

Sep. 16, 2009

Mar. 12, 2010

Oct. 15, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 05, 2008

Warrants [Member]

Warrants [Member]

Warrants [Member]

Warrants Two [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registered direct offering of common stock

'

'

150,000

'

'

'

'

'

'

'

'

'

1,133,500

230,769

17,187

1,151,487

'

'

Purchase price of common stock under first registered direct offering

'

'

$30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants sold

'

'

'

'

'

'

'

'

112,500

'

150,000

'

'

'

'

'

'

'

Gross proceeds from common stock and warrant, net of issuance cost

'

$5,600,000

$4,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock purchase by investor

'

75.00%

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

$28

'

'

'

'

'

'

$35.40

'

'

$37.40

'

'

'

'

'

'

Warrant to purchase unit

'

'

'

'

'

'

'

'

7,500

56,675

11,538

'

'

'

'

'

'

'

Warrants to placement agent, expiration date

9-Dec-12

'

'

'

'

'

'

'

19-Dec-12

'

'

'

'

'

'

'

'

'

Unit exercise price

$5

$26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price for agency

$12.80

$32.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance registered common stock units

2,266,998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds before payment of offering fees and expenses

11,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds after payment of offering fees and expenses

10,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to purchase common stock each unit

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase shares of common stock

0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

469,331

Common stock issued upon exercise of warrant

'

'

'

'

'

'

'

'

'

566,750

'

'

'

'

'

'

'

'

Placement agent fees and Offering expenses

793,449

'

'

871,833

871,833

'

871,833

'

'

'

'

'

'

'

'

'

'

'

Maximum amount of stocks and debt securities issuable

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

Registered direct offering of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

524,393

'

Proceeds from issuance of common stock

'

'

'

$65,743

'

$4,530,129

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Additional4

Stockholders' Equity - Additional Information 4 (Detail) (USD $)

0 Months Ended

12 Months Ended

120 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

Dec. 20, 2011

Nov. 17, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Jul. 17, 2013

Sep. 16, 2009

19-May-05

Dec. 31, 2010

Dec. 20, 2011

Dec. 31, 2010

Dec. 02, 2010

Jul. 31, 2013

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2012

Apr. 30, 2013

Apr. 30, 2013

Apr. 30, 2013

Dec. 20, 2011

Dec. 20, 2011

Dec. 20, 2011

Product

Empire Asset Management [Member]

SourceOne Global Partners, LLC [Member]

Warrants [Member]

Warrants [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

No Warrant Coverage [Member]

At-the-market Transaction [Member]

At-the-market Transaction [Member]

Securities Purchase Agreement With Current Institutional Investor [Member]

Securities Purchase Agreement With Current Institutional Investor [Member]

Securities Purchase Agreement [Member]

License Fee [Member]

License Fee [Member]

License Fee [Member]

Restricted Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

SourceOne Global Partners, LLC [Member]

Nutraceutical, Pharmaceutical and Medical Food Product [Member]

Nutraceutical, Pharmaceutical and Medical Food Product [Member]

Restricted Stock [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of products in portfolio under license agreement

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of license under license agreement

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Automatic renewal period for license term

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fees payable for technology access license

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for payment of license fees

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value per share of shares issued for payment of license fees

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Par value of common stock shares against which warrants are exchanged

'

'

$0.00

$0.00

'

'

$0.00

$0.00

'

$0.00

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exchange option expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Dec-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares accepted for cancellation under warrant exchange

'

'

'

'

'

346,590

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock shares accepted for cancellation under warrant exchange

'

'

'

'

'

67.49%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares issued under warrant

'

'

'

'

'

115,530

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Current fair value of common stock

'

'

'

'

'

'

'

'

'

'

'

'

1,419,761

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Market value of shares issued under warrant

'

'

'

'

'

901,139

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of warrants

'

'

'

'

'

518,622

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facilitation fees paid

'

'

'

'

'

'

'

'

'

'

44,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License fee, equity investment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

750,000

'

License fee, equity investment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

License agreement, escrow shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

Purchase price of common stock under first registered direct offering

'

'

'

'

'

'

'

'

$30

'

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock premium

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.60

'

'

'

'

'

'

'

$10

Common stock, shares issued

'

'

8,810,624

6,460,586

'

'

8,810,624

'

'

'

'

'

'

'

'

'

'

'

'

'

895,000

17,187

260,000

'

'

'

'

'

'

Net proceeds from equity financing

'

'

3,692,844

6,396,311

'

'

91,722,449

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

65,743

1,900,000

'

'

'

'

'

'

Proceeds from issuance of common stock

'

'

65,743

'

4,530,129

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,400,000

'

'

'

'

'

'

'

'

Sell to the Investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,012

'

'

'

'

'

Total purchase price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

Placement agent warrants issued under securities purchase agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,087

'

'

'

'

'

Placement agent warrants, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.275

'

'

'

'

'

Placement agent warrants, expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27-Aug-15

'

'

'

'

'

Closing Sell to the investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,356

'

'

'

Net Proceeds from issuance of Preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,532,000

'

'

'

'

'

'

2,160,000

'

'

'

Second closing sell to the investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,656

'

'

'

'

'

'

'

'

'

'

Reverse stock split of outstanding common stocks for each stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

Conversion of Preferred Stock convertible preferred stock into common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,512

'

'

'

'

'

'

'

'

'

'

Conversion of Preferred Stock convertible preferred stock into common stock, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,332,851

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500

0

1,500

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock, liquidation preference value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

1,000

1,000

'

'

'

'

'

'

'

'

'

'

Maximum beneficial ownership percentage for conversion of preferred stock into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.99%

'

'

'

'

'

'

'

'

'

'

Conversion Price of preferred stock after effect of reverse stock split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.82

'

'

'

'

'

'

'

'

'

'

Conversion Price of preferred stock subsequently reset

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.02

'

'

'

'

'

'

'

'

'

'

Weighted average price exceeds of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Right to force conversion if the volume weighted average price for our common stock exceeds $12.00 per share for 25 trading days during a 30 consecutive trading day period and certain other equity conditions are met.

'

'

'

'

'

'

'

'

'

Deemed preferred dividend feature amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$172,861

$233,011

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Additional5

Stockholders' Equity - Additional Information 5 (Detail) (USD $)	12 Months Ended				0 Months Ended	12 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Jul. 10, 2006	Dec. 31, 2012	Jul. 10, 2012	Jul. 10, 2006
			Warrants [Member]	2005 Equity Incentive Plan [Member]	Stockholder Rights Plan [Member]	Stockholder Rights Plan [Member]	Stockholder Rights Plan [Member]	Stockholder Rights Plan [Member]
					Right			Series A Preferred Stock [Member]
Stockholders Equity [Line Items]	'	'	'	'	'	'	'	'
No of right for each share	'	'	'	'	1	'	'	'
Description Of Event For Occurrence Of Right	'	'	'	'	'	'	'Acquisition of, 15% or more of our common stock	'
Redemption of right	'	'	'	'	'	'	'	0.001
Portion of newly created Series A Preferred Stock for each Right	'	'	'	'	'	'	0.001	'
Series A Junior Participating Preferred Stock , Exercise Price	'	'	'	'	'	'	$40	'
Expiration of plan	'	'	'	'	'	10-Jul-16	'	'
Common stock reserved for issuance	'	'	'	283,292	'	'	'	'
New grants receivable	$0	'	'	'	'	'	'	'
Unvested stock-based compensation at fair value of remaining shares	0	'	'	'	'	'	'	'
Stock option compensation expense, recognized	40,750	169,746	'	'	'	'	'	'
Intrinsic value of options outstanding	0	'	0	'	'	'	'	'
Intrinsic value of options exercisable	$0	'	$0	'	'	'	'	'

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Available Outstanding Shares for Future Issuance (Detail) (2005 Equity Incentive Plan [Member])	Dec. 31, 2013
2005 Equity Incentive Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
2005 Equity Incentive Plan, Shares Outstanding	144,000
2005 Equity Incentive Plan, Shares Available for Issuance	139,058

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Granted Stock Options and Warrants (Detail) (Stock Option and Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013
03/12/12 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Grant Date	12-Mar-12
Quantity Issued	2,500
Expected Life (Years)	'4 years 6 months 29 days
Strike Price	$14.80
Volatility rate	99.00%
Dividend Yield	0.00%
Risk-Free Interest Rate	0.85%
Grant Date Fair Value Per Option	$0.16
Aggregate Fair Value	$8,000
11/05/12 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Grant Date	5-Nov-12
Quantity Issued	2,500
Expected Life (Years)	'4 years 4 months 24 days
Strike Price	$14.80
Volatility rate	98.00%
Dividend Yield	0.00%
Risk-Free Interest Rate	0.64%
Grant Date Fair Value Per Option	$0.09
Aggregate Fair Value	$4,500

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity under Equity Incentive Plan and Warrants Issued Outside Plan (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Number of Options or Warrants, Balance outstanding, Beginning Balance	177,750	179,234	'
Number of Options or Warrants, Granted	0	5,000	'
Number of Options or Warrants, Exercised	'	'	'
Number of Options or Warrants, Cancelled	'	-2,500	'
Number of Options or Warrants, Cancelled (unvested)	-2,844	-3,984	'
Number of Options or Warrants, Expired (vested)	-30,906	'	'
Number of Options or Warrants, Balance outstanding, Ending Balance	144,000	177,750	179,234
Weighted Average Exercise Price, Balance outstanding, Beginning Balance	$33.40	$33.40	'
Number of Options or Warrants, Exercisable, Ending Balance	144,000	'	'
Weighted Average Exercise Price, Granted	$0	$14.80	'
Weighted Average Exercise Price, Exercised	'	'	'
Weighted Average Exercise Price, Cancelled	'	$14.80	'
Weighted Average Exercise Price, Cancelled (unvested)	$14.80	$18.80	'
Weighted Average Exercise Price, Expired (vested)	$41.70	'	'
Weighted Average Exercise Price, Balance outstanding, Ending Balance	$31.74	$33.40	$33.40
Weighted Average Exercise Price, Exercisable, Ending Balance	$31.80	'	'
Weighted Average Remaining Contractual Life (in years), Granted	'0 years	'4 years 6 months	'
Weighted Average Remaining Contractual Life (in years), Exercised	'	'	'
Weighted Average Remaining Contractual Life (in years), Cancelled	'	'0 years	'
Weighted Average Remaining Contractual Life (in years), Cancelled (unvested)	'0 years	'0 years	'
Weighted Average Remaining Contractual Life (in years), Expired (vested)	'0 years	'	'
Weighted Average Remaining Contractual Life (in years), Balance	'2 years 1 month 6 days	'2 years 9 months 18 days	'3 years 9 months 18 days
Weighted Average Remaining Contractual Life (in years), Exercisable, Ending Balance	'2 years 1 month 6 days	'	'

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Warrant Activity (Detail) (Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Balance outstanding, Beginning, Number of Warrants	1,369,321	1,582,492	'
Warrants issued, Number of Warrants	44,088	'	'
Warrants exercised, Number of Warrants	0	-137	'
Warrants expired, Number of Warrants	-434,579	-213,034	'
Warrants cancelled, Number of Warrants	'	'	'
Balance outstanding, Ending, Number of Warrants	978,830	1,369,321	1,582,492
Balance outstanding, Beginning, Weighted Average Exercise Price	$19	$20.40	'
Warrants exercisable, Ending, Number of Warrants	978,830	'	'
Warrants issued, Weighted Average Exercise Price	$2.28	'	'
Warrants exercised, Weighted Average Exercise Price	$0	$5.60	'
Warrants expired, Weighted Average Exercise Price	$15.72	$19.80	'
Warrants cancelled, Weighted Average Exercise Price	'	'	'
Balance outstanding, Ending, Weighted Average Exercise Price	$19.82	$19	$20.40
Warrants exercisable at December 31, 2013, Weighted Average Exercise Price	$19.82	'	'
Warrants issued, Weighted Average Remaining Contractual Life (in years)	'	'	'
Warrants exercised, Weighted Average Remaining Contractual Life (in years)	'	'	'
Warrants expired, Weighted Average Remaining Contractual Life (in years)	'	'	'
Warrants cancelled, Weighted Average Remaining Contractual Life (in years)	'	'	'
Balance outstanding, Weighted Average Remaining Contractual Life (in years)	'1 year 10 months 24 days	'2 years 1 month 6 days	'3 years 9 months 18 days
Warrants exercisable at December 31, 2013, Weighted Average Remaining Contractual Life (in years)	'1 year 10 months 24 days	'	'

Segment_Information_Additional

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Segment	Segment
Segment Reporting [Abstract]	'	'
Number of segments	1	2

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2011

Jul. 17, 2013

Dec. 31, 2012

19-May-05

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Feb. 28, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Tranches

Tranche 2 [Member]

Tranche 3 [Member]

Tranche 4 [Member]

Tranche 5 [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Board Of Directors By Two Members [Member]

Size of Board of Director Increased by One [Member]

Directors, Officers and Chief Medical Advisor [Member]

Agreement

March 31, 2014 [Member]

April 30, 2014 [Member]

May 30, 2014 [Member]

June 30, 2014 [Member]

Tranche 3 [Member]

Tranche 4 [Member]

Tranche 5 [Member]

April 15, 2014 [Member]

May 15, 2014 [Member]

June 16, 2014 [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration date

'February 28, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of agreements

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Financing under Stock Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,000,000

$5,000,000

'

Purchase of shares

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

Common stock share premium percentage

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Common stock shares sold

8,810,624

'

'

6,460,586

'

714,286

'

'

'

'

'

'

'

'

'

'

Common stock per share

$0.00

'

$0.00

$0.00

$0.00

$0.70

'

'

'

'

'

'

'

'

'

'

Purchase price for each subsequent tranche, in percentage

'

'

'

'

'

110.00%

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

$65,743

$4,530,129

'

'

'

'

$1,500,000

$1,000,000

$1,000,000

$1,000,000

$300,000

$300,000

$300,000

'

'

'

Number of additional tranches

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Common stock warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,457,100

Common stock warrants, term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Common stock warrants, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.80

Common stock warrants, premium percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57.00%